SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Vivos Inc. – ‘10-Q’ for 9/30/22 – ‘XML’

On:  Wednesday, 10/19/22, at 4:02pm ET   ·   For:  9/30/22   ·   Accession #:  1493152-22-28874   ·   File #:  0-53497

Previous ‘10-Q’:  ‘10-Q’ on 7/25/22 for 6/30/22   ·   Next:  ‘10-Q’ on 5/4/23 for 3/31/23   ·   Latest:  ‘10-Q’ on 11/6/23 for 9/30/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/19/22  Vivos Inc.                        10-Q        9/30/22   41:5.6M                                   M2 Compliance LLC/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.57M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     20K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     20K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     16K 
10: R1          Cover                                               HTML     60K 
11: R2          Condensed Balance Sheets                            HTML     91K 
12: R3          Condensed Balance Sheets (Parenthetical)            HTML     36K 
13: R4          Condensed Statements of Operations (Unaudited)      HTML     88K 
14: R5          Condensed Statement of Changes in Stockholders'     HTML    117K 
                Equity (Unaudited)                                               
15: R6          Condensed Statements of Cash Flows (Unaudited)      HTML     83K 
16: R7          Basis of Presentation and Significant Accounting    HTML    119K 
                Policies                                                         
17: R8          Related Party Transactions                          HTML     28K 
18: R9          Convertible Notes Payable                           HTML     21K 
19: R10         Stockholders? Equity                                HTML     85K 
20: R11         Common Stock Options, Warrants and Restricted       HTML    175K 
                Stock Units                                                      
21: R12         Commitment                                          HTML     19K 
22: R13         Basis of Presentation and Significant Accounting    HTML    167K 
                Policies (Policies)                                              
23: R14         Basis of Presentation and Significant Accounting    HTML     29K 
                Policies (Tables)                                                
24: R15         Common Stock Options, Warrants and Restricted       HTML    149K 
                Stock Units (Tables)                                             
25: R16         Schedule of Depreciation Estimated Useful Life      HTML     26K 
                (Details)                                                        
26: R17         Schedule of Dilutive Earnings Per Share (Details)   HTML     26K 
27: R18         Basis of Presentation and Significant Accounting    HTML     71K 
                Policies (Details Narrative)                                     
28: R19         Related Party Transactions (Details Narrative)      HTML     63K 
29: R20         Convertible Notes Payable (Details Narrative)       HTML     18K 
30: R21         Stockholders? Equity (Details Narrative)            HTML    205K 
31: R22         Schedule of Changes in Stock Option (Details)       HTML     63K 
32: R23         Schedule of Changes in Stock Warrants (Details)     HTML     61K 
33: R24         Schedule of Assumptions Used in Fair Value          HTML     26K 
                Measurement (Details)                                            
34: R25         Schedule of Changes in Restricted Stock Units       HTML     36K 
                (Details)                                                        
35: R26         Common Stock Options, Warrants and Restricted       HTML    157K 
                Stock Units (Details Narrative)                                  
36: R27         Commitment (Details Narrative)                      HTML     22K 
39: XML         IDEA XML File -- Filing Summary                      XML     66K 
37: XML         XBRL Instance -- form10-q_htm                        XML   1.41M 
38: EXCEL       IDEA Workbook of Financial Reports                  XLSX    110K 
 6: EX-101.CAL  XBRL Calculations -- rdgl-20220930_cal               XML     85K 
 7: EX-101.DEF  XBRL Definitions -- rdgl-20220930_def                XML    455K 
 8: EX-101.LAB  XBRL Labels -- rdgl-20220930_lab                     XML    752K 
 9: EX-101.PRE  XBRL Presentations -- rdgl-20220930_pre              XML    597K 
 5: EX-101.SCH  XBRL Schema -- rdgl-20220930                         XSD     89K 
40: JSON        XBRL Instance as JSON Data -- MetaLinks              253±   371K 
41: ZIP         XBRL Zipped Folder -- 0001493152-22-028874-xbrl      Zip    223K

‘XML’   —   XBRL Instance — form10-q_htm

This Document is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:RDGL="http://radiogel.com/20220930" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="rdgl-20220930.xsd" xlink:type="simple"/>
<context id="From2022-01-01to2022-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="AsOf2022-10-18">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2022-10-18 </instant>
</period>
</context>
<context id="AsOf2022-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2021-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2022-09-30_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2022-09-30_custom_SeriesCConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesCConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesCConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-06-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-04-012021-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2021-04-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2021-09-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2021-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesAPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesBPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesCPreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:AdditionalPaidInCapitalSeriesCPreferredMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="From2021-09-142021-09-15">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2021-09-14 </startDate>
<endDate> 2021-09-15 </endDate>
</period>
</context>
<context id="AsOf2021-09-15">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2021-09-15 </instant>
</period>
</context>
<context id="From2022-07-272022-07-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2022-07-27 </startDate>
<endDate> 2022-07-31 </endDate>
</period>
</context>
<context id="AsOf2022-07-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2022-07-31 </instant>
</period>
</context>
<context id="From2022-10-302022-10-31_us-gaap_SubsequentEventMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-10-30 </startDate>
<endDate> 2022-10-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_srt_MinimumMember_custom_ProductionEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> RDGL:ProductionEquipmentMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_srt_MaximumMember_custom_ProductionEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> RDGL:ProductionEquipmentMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_srt_MinimumMember_us-gaap_OfficeEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:OfficeEquipmentMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_srt_MaximumMember_us-gaap_OfficeEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:OfficeEquipmentMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:FurnitureAndFixturesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> us-gaap:FurnitureAndFixturesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_custom_RestrictedStockUnitsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> RDGL:RestrictedStockUnitsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_RestrictedStockUnitsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> RDGL:RestrictedStockUnitsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_custom_CommonStockOptionsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> RDGL:CommonStockOptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_CommonStockOptionsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> RDGL:CommonStockOptionsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_custom_CommonStockWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> RDGL:CommonStockWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_CommonStockWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> RDGL:CommonStockWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-06-012021-06-30_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-06-012021-06-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-06-012021-06-30_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-05-012021-05-31_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-01 </startDate>
<endDate> 2021-05-31 </endDate>
</period>
</context>
<context id="From2021-06-012021-06-30_srt_ChiefExecutiveOfficerMember30986031">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="AsOf2021-09-30_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-09-30 </instant>
</period>
</context>
<context id="From2021-09-012021-09-30_srt_ChiefExecutiveOfficerMember_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-09-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="AsOf2022-03-31_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="From2022-03-012022-03-31_srt_ChiefExecutiveOfficerMember_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_ConvertibleNotesPayableMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2018-10-08_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-10-08 </instant>
</period>
</context>
<context id="AsOf2019-03-27_custom_SeriesCConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesCConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-03-27 </instant>
</period>
</context>
<context id="AsOf2015-06-30_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2015-06-30 </instant>
</period>
</context>
<context id="AsOf2016-03-31_custom_SeriesAConvertiblePreferredStockMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2016-03-31 </instant>
</period>
</context>
<context id="AsOf2016-03-31_custom_SeriesAConvertiblePreferredStockMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2016-03-31 </instant>
</period>
</context>
<context id="From2015-06-012015-06-30_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2015-06-01 </startDate>
<endDate> 2015-06-30 </endDate>
</period>
</context>
<context id="From2021-06-012021-06-30_srt_ChiefExecutiveOfficerMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="AsOf2018-10-31_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-10-31 </instant>
</period>
</context>
<context id="From2018-10-012018-10-31_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2018-10-01 </startDate>
<endDate> 2018-10-31 </endDate>
</period>
</context>
<context id="From2021-12-012021-12-31_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-12-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-12-012021-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-12-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2019-03-31_custom_SeriesCConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesCConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-03-31 </instant>
</period>
</context>
<context id="From2019-03-012019-03-31_custom_SeriesCConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> RDGL:SeriesCConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-03-01 </startDate>
<endDate> 2019-03-31 </endDate>
</period>
</context>
<context id="From2022-03-012022-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-03-012022-03-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-06-022022-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2022-06-02 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-07-052022-07-07_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-05 </startDate>
<endDate> 2022-07-07 </endDate>
</period>
</context>
<context id="AsOf2022-07-07">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<instant> 2022-07-07 </instant>
</period>
</context>
<context id="AsOf2022-07-07_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-07-07 </instant>
</period>
</context>
<context id="From2022-07-052022-07-07_custom_JuneTwoThousandTwentyFiveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis"> RDGL:JuneTwoThousandTwentyFiveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-05 </startDate>
<endDate> 2022-07-07 </endDate>
</period>
</context>
<context id="AsOf2022-07-07_custom_JuneTwoThousandTwentyFiveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis"> RDGL:JuneTwoThousandTwentyFiveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-07-07 </instant>
</period>
</context>
<context id="From2022-07-052022-07-07_custom_DecemberTwoThousandTwentyTwoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis"> RDGL:DecemberTwoThousandTwentyTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-05 </startDate>
<endDate> 2022-07-07 </endDate>
</period>
</context>
<context id="AsOf2022-07-07_custom_DecemberTwoThousandTwentyTwoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardDateAxis"> RDGL:DecemberTwoThousandTwentyTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-07-07 </instant>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_AccountsPayableMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis"> us-gaap:AccountsPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-01-31_us-gaap_AccountsPayableMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis"> us-gaap:AccountsPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-01-31 </endDate>
</period>
</context>
<context id="From2021-05-012021-05-31_us-gaap_AccountsPayableMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis"> us-gaap:AccountsPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-01 </startDate>
<endDate> 2021-05-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-01-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-01-31 </endDate>
</period>
</context>
<context id="From2021-03-012021-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-03-012021-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-09-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-09-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-09-30_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="AsOf2020-12-31_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2020-01-012020-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2022-09-30_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_StockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-09-30_us-gaap_StockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-01-082021-01-29_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-08 </startDate>
<endDate> 2021-01-29 </endDate>
</period>
</context>
<context id="From2021-01-082021-01-29_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-08 </startDate>
<endDate> 2021-01-29 </endDate>
</period>
</context>
<context id="AsOf2021-03-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-31 </instant>
</period>
</context>
<context id="From2021-03-012021-03-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-01 </startDate>
<endDate> 2021-03-31 </endDate>
</period>
</context>
<context id="From2021-07-092021-09-24_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-09 </startDate>
<endDate> 2021-09-24 </endDate>
</period>
</context>
<context id="From2021-07-092021-09-24_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-09 </startDate>
<endDate> 2021-09-24 </endDate>
</period>
</context>
<context id="From2021-10-012021-10-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-10-01 </startDate>
<endDate> 2021-10-31 </endDate>
</period>
</context>
<context id="From2021-10-012021-10-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-10-01 </startDate>
<endDate> 2021-10-31 </endDate>
</period>
</context>
<context id="From2022-05-292022-06-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-05-29 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="AsOf2022-07-07_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-07-07 </instant>
</period>
</context>
<context id="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-02 </startDate>
<endDate> 2021-05-03 </endDate>
</period>
</context>
<context id="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_ConsultantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> RDGL:ConsultantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-02 </startDate>
<endDate> 2021-05-03 </endDate>
</period>
</context>
<context id="From2021-06-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_OneConsultantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> RDGL:OneConsultantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-01 </startDate>
<endDate> 2021-06-30 </endDate>
</period>
</context>
<context id="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> RDGL:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-02 </startDate>
<endDate> 2021-05-03 </endDate>
</period>
</context>
<context id="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> RDGL:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-02 </startDate>
<endDate> 2021-05-03 </endDate>
</period>
</context>
<context id="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_custom_OnTheGrantDateMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementScenarioAxis"> RDGL:OnTheGrantDateMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> RDGL:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-02 </startDate>
<endDate> 2021-05-03 </endDate>
</period>
</context>
<context id="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> RDGL:EmploymentAgreementMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis"> us-gaap:ShareBasedCompensationAwardTrancheOneMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-02 </startDate>
<endDate> 2021-05-03 </endDate>
</period>
</context>
<context id="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> RDGL:EmploymentAgreementMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VestingAxis"> us-gaap:ShareBasedCompensationAwardTrancheTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-02 </startDate>
<endDate> 2021-05-03 </endDate>
</period>
</context>
<context id="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_custom_BoardOfDirectorsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> RDGL:BoardOfDirectorsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> RDGL:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-02 </startDate>
<endDate> 2021-05-03 </endDate>
</period>
</context>
<context id="From2022-02-022022-02-03_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-02-02 </startDate>
<endDate> 2022-02-03 </endDate>
</period>
</context>
<context id="From2022-03-022022-03-03_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:ChiefExecutiveOfficerMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-03-02 </startDate>
<endDate> 2022-03-03 </endDate>
</period>
</context>
<context id="From2022-05-302022-06-01_custom_ConsultantMember_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> RDGL:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-05-30 </startDate>
<endDate> 2022-06-01 </endDate>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_WarrantMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_WarrantMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_WarrantMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_WarrantMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="From2022-01-012022-09-30_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2020-12-31_custom_RestrictedStockUnitsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> RDGL:RestrictedStockUnitsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_RestrictedStockUnitsMember30990828">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> RDGL:RestrictedStockUnitsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_RestrictedStockUnitsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> RDGL:RestrictedStockUnitsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2022-01-012022-09-30_custom_RestrictedStockUnitsMember30990859">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> RDGL:RestrictedStockUnitsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="AsOf2022-09-30_custom_RestrictedStockUnitsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> RDGL:RestrictedStockUnitsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="From2019-06-032019-06-04_custom_EmploymentAgreementMember_custom_DrMichaelKKorenkoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001449349 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> RDGL:DrMichaelKKorenkoMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> RDGL:EmploymentAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-06-03 </startDate>
<endDate> 2019-06-04 </endDate>
</period>
</context>
<unit id="USD">
<measure> iso4217:USD </measure>
</unit>
<unit id="Shares">
<measure> shares </measure>
</unit>
<unit id="USDPShares">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> shares </measure>
</unitDenominator>
</divide>
</unit>
<unit id="Pure">
<measure> pure </measure>
</unit>
<dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-09-30"> 0001449349 </dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="From2022-01-01to2022-09-30"> false </dei:AmendmentFlag>
<dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-09-30"> Q3 </dei:DocumentFiscalPeriodFocus>
<dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-09-30"> --12-31 </dei:CurrentFiscalYearEndDate>
<us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" id="xdx2ixbrl0045" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="AsOf2022-09-30" id="xdx2ixbrl0074" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="AsOf2021-12-31" id="xdx2ixbrl0075" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestExpense contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0234" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestExpense contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0236" unitRef="USD" xsi:nil="true"/>
<RDGL:ForgivenessOfDebt contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0239" unitRef="USD" xsi:nil="true"/>
<RDGL:ForgivenessOfDebt contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0241" unitRef="USD" xsi:nil="true"/>
<RDGL:ForgivenessOfDebt contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0242" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0246" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0247" unitRef="USD" xsi:nil="true"/>
<us-gaap:NonoperatingIncomeExpense contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0251" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxExpenseBenefit contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0259" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxExpenseBenefit contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0260" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxExpenseBenefit contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0261" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxExpenseBenefit contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0262" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0298" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0299" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0300" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0301" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0302" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0303" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0311" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0312" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0313" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0314" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0316" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0324" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0325" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0326" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0327" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0328" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0329" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0332" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0337" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0338" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0339" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0340" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0341" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0342" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0345" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0346" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0350" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0351" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0352" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0353" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0354" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0355" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0358" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0361" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0362" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0364" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0365" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0366" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0367" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0368" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0391" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0392" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0393" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0394" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0395" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0396" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0399" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0400" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0406" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0407" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0408" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0409" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0413" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0419" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0420" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0421" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0422" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0423" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0424" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0427" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0432" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0433" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0434" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0435" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0436" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0437" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0438" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0440" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0443" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0444" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0445" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0446" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0447" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0448" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0449" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0450" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0473" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0474" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0475" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0476" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0477" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0478" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0481" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0482" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0486" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0487" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0488" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0489" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0490" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0491" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0492" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0493" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0535" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0536" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0537" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0538" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0539" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0540" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0543" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0548" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0549" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0550" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0551" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0552" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0553" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0556" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31" id="xdx2ixbrl0557" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0561" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0562" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0563" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0564" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0565" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0566" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0567" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0569" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0572" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0573" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0574" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0575" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0576" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0577" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0578" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0579" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0602" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0603" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0604" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0605" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0606" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0607" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0608" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0610" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0613" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0614" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0615" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0616" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0617" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0618" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0619" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0620" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0662" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0663" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0664" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0665" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0666" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0667" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0670" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0675" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0676" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0677" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0678" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0679" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0680" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0683" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0688" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0689" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0690" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0691" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0692" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0693" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0694" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0695" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0696" unitRef="USD" xsi:nil="true"/>
<RDGL:StockIssuedDuringPeriodValueFractionalAdjustment contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0697" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0701" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0702" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0703" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0704" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0705" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0706" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0707" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0709" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0712" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0713" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0714" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0715" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0716" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0717" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0718" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0719" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0720" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0721" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0723" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" id="xdx2ixbrl0724" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0725" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" id="xdx2ixbrl0726" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0727" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" id="xdx2ixbrl0728" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0729" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0730" unitRef="USD" xsi:nil="true"/>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0782" unitRef="USD" xsi:nil="true"/>
<RDGL:ForgivenessOfDebt contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0790" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0805" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0808" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaidNet contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0838" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaidNet contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0839" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaidNet contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0841" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaidNet contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0842" unitRef="USD" xsi:nil="true"/>
<RDGL:ConversionOfNotesPayableRelatedPartiesAndAccruedInterestIntoCommonStock contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0847" unitRef="USD" xsi:nil="true"/>
<RDGL:RsusVestedIntoCommonStock contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0853" unitRef="USD" xsi:nil="true"/>
<RDGL:StockOptionsExercisedForRecissionOfCommonAndPreferredStock contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0859" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1172" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1174" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:WeightedAverageExercisePricePerShareOptionsGranted contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1176" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1180" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:WeightedAverageExercisePricePerShareOptionsExercised contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1182" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1186" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:WeightedAverageExercisePricePerShareOptionsExpired contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1188" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1202" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1204" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:WeightedAverageExercisePricePerShareOptionsGranted contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1206" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1208" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1210" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:WeightedAverageExercisePricePerShareOptionsExercised contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1212" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1214" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1216" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:WeightedAverageExercisePricePerShareOptionsExpired contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1218" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:ExcercisePriceWarrantsGrantedMinimum contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1271" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1275" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1279" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" id="xdx2ixbrl1295" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:ExcercisePriceWarrantsGrantedMinimum contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" id="xdx2ixbrl1297" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" id="xdx2ixbrl1301" unitRef="USDPShares" xsi:nil="true"/>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" id="xdx2ixbrl1305" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl1345" unitRef="Pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2021-01-012021-12-31" id="xdx2ixbrl1347" unitRef="Pure" xsi:nil="true"/>
<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-03-31_us-gaap_WarrantMember" id="xdx2ixbrl1363"> P2Y </us-gaap:WarrantsAndRightsOutstandingTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2021-01-012021-12-31_custom_RestrictedStockUnitsMember30990828" id="xdx2ixbrl1409" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2021-01-012021-12-31_custom_RestrictedStockUnitsMember30990828" id="xdx2ixbrl1411" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="From2021-01-012021-12-31_custom_RestrictedStockUnitsMember30990828" id="xdx2ixbrl1413" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2022-01-012022-09-30_custom_RestrictedStockUnitsMember30990859" id="xdx2ixbrl1425" unitRef="USDPShares" xsi:nil="true"/>
<dei:DocumentType contextRef="From2022-01-01to2022-09-30"> 10-Q </dei:DocumentType>
<dei:DocumentQuarterlyReport contextRef="From2022-01-01to2022-09-30"> true </dei:DocumentQuarterlyReport>
<dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-09-30"> 2022-09-30 </dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-09-30"> 2022 </dei:DocumentFiscalYearFocus>
<dei:DocumentTransitionReport contextRef="From2022-01-01to2022-09-30"> false </dei:DocumentTransitionReport>
<dei:EntityFileNumber contextRef="From2022-01-01to2022-09-30"> 000-53497 </dei:EntityFileNumber>
<dei:EntityRegistrantName contextRef="From2022-01-01to2022-09-30"> VIVOS INC </dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-09-30"> DE </dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-09-30"> 80-0138937 </dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-09-30"> 719 Jadwin Avenue </dei:EntityAddressAddressLine1>
<dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-09-30"> Richland </dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-09-30"> WA </dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-09-30"> 99352 </dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="From2022-01-01to2022-09-30"> (509) </dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="From2022-01-01to2022-09-30"> 736-4000 </dei:LocalPhoneNumber>
<dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-09-30"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-09-30"> Yes </dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory contextRef="From2022-01-01to2022-09-30"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="From2022-01-01to2022-09-30"> true </dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-09-30"> false </dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany contextRef="From2022-01-01to2022-09-30"> false </dei:EntityShellCompany>
<dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-10-18" decimals="INF" unitRef="Shares"> 359891255 </dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 1987732 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1606123 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 13000 </us-gaap:AccountsReceivableNetCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 45418 </us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 28175 </us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 2046150 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1634298 </us-gaap:AssetsCurrent>
<us-gaap:Assets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 2046150 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1634298 </us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 160953 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 166915 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 160953 </us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 166915 </us-gaap:LiabilitiesCurrent>
<us-gaap:Liabilities contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 160953 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 166915 </us-gaap:Liabilities>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2022-09-30" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockValue contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:PreferredStockValue>
<us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="AsOf2022-09-30_custom_SeriesAConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:AdditionalPaidInCapitalPreferredStock>
<us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="AsOf2021-12-31_custom_SeriesAConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:AdditionalPaidInCapitalPreferredStock>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockValue contextRef="AsOf2022-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 200 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 200 </us-gaap:PreferredStockValue>
<us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="AsOf2022-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 290956 </us-gaap:AdditionalPaidInCapitalPreferredStock>
<us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="AsOf2021-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 290956 </us-gaap:AdditionalPaidInCapitalPreferredStock>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-09-30_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-09-30_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockValue contextRef="AsOf2022-09-30_custom_SeriesCConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="AsOf2022-09-30_custom_SeriesCConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:PreferredStockValue>
<us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="AsOf2022-09-30_custom_SeriesCConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 500507 </us-gaap:AdditionalPaidInCapitalPreferredStock>
<us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 500507 </us-gaap:AdditionalPaidInCapitalPreferredStock>
<us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="AsOf2022-09-30_custom_SeriesCConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 500507 </us-gaap:AdditionalPaidInCapitalPreferredStock>
<us-gaap:AdditionalPaidInCapitalPreferredStock contextRef="AsOf2021-12-31_custom_SeriesCConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 500507 </us-gaap:AdditionalPaidInCapitalPreferredStock>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2022-09-30" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 950000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 950000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 359891255 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 359891255 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 343530678 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 343530678 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 359891 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 343531 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 70739104 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 68573142 </us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> -78850375 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> -77085867 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 1885197 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1467383 </us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 2046150 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1634298 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 30000 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 14887 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 6500 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> 14887 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:CostOfGoodsAndServicesSold contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 18053 </us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 6000 </us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 13035 </us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> 6000 </us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:GrossProfit contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 11947 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 8887 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -6535 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> 8887 </us-gaap:GrossProfit>
<us-gaap:ProfessionalFees contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 1191807 </us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 1786028 </us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 93300 </us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> 55583 </us-gaap:ProfessionalFees>
<us-gaap:LaborAndRelatedExpense contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 208818 </us-gaap:LaborAndRelatedExpense>
<us-gaap:LaborAndRelatedExpense contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 202428 </us-gaap:LaborAndRelatedExpense>
<us-gaap:LaborAndRelatedExpense contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 68163 </us-gaap:LaborAndRelatedExpense>
<us-gaap:LaborAndRelatedExpense contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> 64925 </us-gaap:LaborAndRelatedExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 312066 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 221154 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 70765 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> 60831 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 111352 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 82635 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 38302 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> 22131 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 1824043 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 2292245 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 270530 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> 203470 </us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> -1812096 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -2283358 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -277065 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> -194583 </us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 19628 </us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> 6577 </us-gaap:InterestExpense>
<RDGL:ForgivenessOfDebt contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 129745 </RDGL:ForgivenessOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 47588 </us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -176295 </us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:NonoperatingIncomeExpense contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 47588 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -66178 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> -6577 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> -1764508 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -2349536 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -277065 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> -201160 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:NetIncomeLoss contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> -1764508 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -2349536 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -277065 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> -201160 </us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasic contextRef="From2022-01-01to2022-09-30" decimals="INF" unitRef="USDPShares"> -0.01 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="From2021-01-012021-09-30" decimals="INF" unitRef="USDPShares"> -0.01 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="From2022-07-012022-09-30" decimals="INF" unitRef="USDPShares"> -0.00 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="From2021-07-012021-09-30" decimals="INF" unitRef="USDPShares"> -0.00 </us-gaap:EarningsPerShareBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2022-01-01to2022-09-30" decimals="INF" unitRef="Shares"> 348563383 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2021-01-012021-09-30" decimals="INF" unitRef="Shares"> 321548977 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2022-07-012022-09-30" decimals="INF" unitRef="Shares"> 358750041 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2021-07-012021-09-30" decimals="INF" unitRef="Shares"> 335506200 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2171007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2171 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8857358 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 436653 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 436 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 385235 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 292278591 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 292279 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 64551764 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -74558101 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 32034 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 22500000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 22500 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1777500 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-03-31" decimals="0" unitRef="USD"> 1800000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 1259250 </us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 1259 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 225406 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2021-01-012021-03-31" decimals="0" unitRef="USD"> 226665 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 384445 </us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 384 </us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 49616 </us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-01-012021-03-31" decimals="0" unitRef="USD"> 50000 </us-gaap:StockIssuedDuringPeriodValueOther>
<RDGL:StockIssuedDuringPeriodSharesWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3870428 </RDGL:StockIssuedDuringPeriodSharesWarrantExercises>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 3870 </RDGL:StockIssuedDuringPeriodValueWarrantExercises>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> -3870 </RDGL:StockIssuedDuringPeriodValueWarrantExercises>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 11238 </us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-012021-03-31" decimals="0" unitRef="USD"> 11238 </us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -288189 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-03-31" decimals="0" unitRef="USD"> -288189 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2171007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2171 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8857358 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 436653 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 436 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 385235 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 320292714 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 320292 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 66611654 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -74846290 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD"> 1831748 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 12000000 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 12000 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> -12000 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> -100000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> -100 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> -14900 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 2125000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 2125 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 12875 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 519480 </us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 520 </us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 39480 </us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2021-04-012021-06-30" decimals="0" unitRef="USD"> 40000 </us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1614000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2021-04-012021-06-30" decimals="0" unitRef="USD"> 1614000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -1860187 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2021-04-012021-06-30" decimals="0" unitRef="USD"> -1860187 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 436653 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 436 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 385235 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 334937194 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 334937 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 68266009 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -76706477 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD"> 1625561 </us-gaap:StockholdersEquity>
<RDGL:StockIssuedDuringPeriodSharesWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 838195 </RDGL:StockIssuedDuringPeriodSharesWarrantExercises>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 838 </RDGL:StockIssuedDuringPeriodValueWarrantExercises>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> -838 </RDGL:StockIssuedDuringPeriodValueWarrantExercises>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -201160 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2021-07-012021-09-30" decimals="0" unitRef="USD"> -201160 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 436653 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 436 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 385235 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 335775389 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 335775 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 68265171 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -76907637 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD"> 1424401 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 200 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 290956 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 343530678 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 343531 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 68573142 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -77085867 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1467383 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 76250 </us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 76 </us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 4804 </us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-01-012022-03-31" decimals="0" unitRef="USD"> 4880 </us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<RDGL:StockIssuedDuringPeriodSharesWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 299577 </RDGL:StockIssuedDuringPeriodSharesWarrantExercises>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 300 </RDGL:StockIssuedDuringPeriodValueWarrantExercises>
<RDGL:StockIssuedDuringPeriodValueWarrantExercises contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> -300 </RDGL:StockIssuedDuringPeriodValueWarrantExercises>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 450000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-01-012022-03-31" decimals="0" unitRef="USD"> 450000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -699905 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31" decimals="0" unitRef="USD"> -699905 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 200 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 290956 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 343906505 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 343907 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 69027646 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -77785772 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD"> 1222358 </us-gaap:StockholdersEquity>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 458200 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-04-012022-06-30" decimals="0" unitRef="USD"> 458200 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -787538 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30" decimals="0" unitRef="USD"> -787538 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 200 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 290956 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 343906505 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 343907 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 69485846 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -78573310 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD"> 893020 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 200 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 290956 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 343906505 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 343907 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 69485846 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -78573310 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD"> 893020 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 15000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 15000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1185000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 1200000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 984840 </us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 984 </us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 48258 </us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 49242 </us-gaap:StockIssuedDuringPeriodValueOther>
<RDGL:StockIssuedDuringPeriodSharesFractionalAdjustment contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> -90 </RDGL:StockIssuedDuringPeriodSharesFractionalAdjustment>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 20000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 20000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -277065 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -277065 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 200 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 290956 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 359891255 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 359891 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 70739104 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -78850375 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 1885197 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 2071007 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" decimals="0" unitRef="USD"> 2071 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesAPreferredMember" decimals="0" unitRef="USD"> 8842458 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 200363 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" decimals="0" unitRef="USD"> 200 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesBPreferredMember" decimals="0" unitRef="USD"> 290956 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="INF" unitRef="Shares"> 385302 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" decimals="0" unitRef="USD"> 385 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_AdditionalPaidInCapitalSeriesCPreferredMember" decimals="0" unitRef="USD"> 500507 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 359891255 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 359891 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 70739104 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -78850375 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 1885197 </us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> -1764508 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -2349536 </us-gaap:NetIncomeLoss>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 4880 </us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<RDGL:RestrictedStockUnitsIssuedForServices contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 908200 </RDGL:RestrictedStockUnitsIssuedForServices>
<RDGL:RestrictedStockUnitsIssuedForServices contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 1614000 </RDGL:RestrictedStockUnitsIssuedForServices>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 47588 </us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -176295 </us-gaap:GainsLossesOnExtinguishmentOfDebt>
<RDGL:ForgivenessOfDebt contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 129745 </RDGL:ForgivenessOfDebt>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 13000 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 8887 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 17243 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 14480 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 90868 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 30517 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -66143 </us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 19628 </us-gaap:IncreaseDecreaseInInterestPayableNet>
<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 926117 </us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 1621185 </us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> -838391 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -728351 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 1220000 </us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 1811238 </us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 1220000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 1811238 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 381609 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 1082887 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1606123 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 903704 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 1987732 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-09-30" decimals="0" unitRef="USD"> 1986591 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<RDGL:ConversionOfNotesPayableRelatedPartiesAndAccruedInterestIntoCommonStock contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 50370 </RDGL:ConversionOfNotesPayableRelatedPartiesAndAccruedInterestIntoCommonStock>
<us-gaap:StockIssued1 contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 300 </us-gaap:StockIssued1>
<us-gaap:StockIssued1 contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 4708 </us-gaap:StockIssued1>
<RDGL:RsusVestedIntoCommonStock contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 12000 </RDGL:RsusVestedIntoCommonStock>
<RDGL:AccountsPayableConvertedIntoSharesOfCommonStock contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 49242 </RDGL:AccountsPayableConvertedIntoSharesOfCommonStock>
<RDGL:AccountsPayableConvertedIntoSharesOfCommonStock contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 90000 </RDGL:AccountsPayableConvertedIntoSharesOfCommonStock>
<RDGL:StockOptionsExercisedForRecissionOfCommonAndPreferredStock contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 60000 </RDGL:StockOptionsExercisedForRecissionOfCommonAndPreferredStock>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_805_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z1uXkDpPnEM5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1: <span id="xdx_829_zLsRcYXTkbm4">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed financial statements of Vivos Inc. (the “<i>Company</i>”) have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures required by accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the results of operations of the Company for the period presented. The results of operations for the nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for any future period or the fiscal year ending December 31, 2022 and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 7, 2022.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--BusinessOverviewPolicyTextBlock_zVta8dqAzir5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Overview</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“<i>SMSC</i>”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20220930_zrLjeHVtaNa3" title="Common stock, shares authorized">950,000,000</span> shares of common stock, $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220930_zrwN4Adrqxob" title="Common stock, par value">0.001</span> par value per share, and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20220930_z6EpMe68BHs" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220930_zXTVpGvHWTvk" title="Preferred stock, par value">0.001</span> par value per share.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel<sup>™</sup>, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel <sup>™</sup>should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“<i>FDA</i>”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet<sup>® </sup>for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the FDA’s recommendation, RadioGel<sup>™</sup> will be marketed as “IsoPet<sup>®</sup>” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet<sup>®</sup>” name. IsoPet<sup>® </sup>and RadioGel<sup>™</sup> are used synonymously throughout this document. The only distinction between IsoPet<sup>® </sup>and RadioGel<sup>™</sup> is the FDA’s recommendation that we use “IsoPet<sup>®</sup>” for veterinarian usage, and reserve “RadioGel<sup>™” </sup>for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet<sup>®</sup> for animal therapy, through the Company’s IsoPet<sup>® </sup>Solutions division.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zd01lZ4GBvdh" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IsoPet Solutions</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet<sup>®</sup> testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet<sup>®</sup>. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“<i>RECIST</i>”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet<sup>®</sup>. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet<sup>®</sup> is safe for same day therapy.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effectiveness of IsoPet<sup>®</sup> for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet<sup>®</sup> therapy and will incorporate the improvements suggested by the testing program.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel<sup>™</sup> (under the name IsoPet<sup>®</sup>) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet<sup>®</sup> Solutions division as a separate operating segment in accordance with GAAP.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing in July 2019, the Company recognized its first commercial sale of IsoPet<sup>®</sup>. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet<sup>®</sup> during 2019.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our plan is to incorporate the data assembled from our work with Isopet<sup>®</sup> in animal therapy to support the Company’s efforts in the development of our RadioGel<sup>™</sup> device candidate, including obtaining approval from the <i>FDA</i> to market and sell RadioGel<sup>™</sup> as a Class II medical device. RadioGel<sup>™</sup> is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel<sup>™</sup> is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, less than two microns, yttrium-90 phosphate particles (“<i>Y-90</i>”). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a <span id="xdx_906_eus-gaap--DescriptionOfCreditRiskExposure_c20220101__20220930_zSCxc5FGQU57" title="Description of risk exposure">half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s lead brachytherapy products, including RadioGel<sup>™</sup>, incorporate patented technology developed for Battelle Memorial Institute (“<i>Battelle</i>”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted the Company an exclusive license to patents covering the manufacturing, processing and applications of RadioGel<sup>™</sup> (the “<i>Battelle License</i>”). This exclusive license is to terminate upon the expiration of the last patent included in this agreement (December 2022). Other intellectual property protection includes proprietary production processes and trademark protection in 17 countries.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--IntellectualPropertyPolicyTextBlock_zCly14OeklH9" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual Property</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our original license with Battelle National Laboratory is reached its end of life. During the past several years, in anticipation of this we have expanded our proprietary knowledge and our trademark and patent protection.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have expanded our trademark protection from RadioGel to now include IsoPet. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries<b>.</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet<sup>®</sup> and Radiogel™.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a <span style="background-color: white">continuation-in-part applications</span> number 1774054 in the USA to expand the claims on our particle patent. <span style="background-color: white">T</span>he US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, <span style="background-color: white">US Patent Application Serial No: 16-459,466</span>. <span style="background-color: white">We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.</span></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a hydrogel utility patent in the USA and PCT based on the last eighteen months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are continuously improving our injection system. We completed the development of a syringe shield and vial holder. We are now testing an advanced cooling system to hold the vial and syringes. We are also testing commercially available systems for deep injections, which will be useful in treating lung and pancreatic caners. We are considering filing a provisional patent on these injection system developments.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_842_ecustom--GoingConcernPolicyTextBlock_zTOxiqmK4r5h" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_pn5n6_c20220101__20220930_zfSiNXY1Pw94" title="Current operation activities">2.5</span> million annually to maintain current operating activities.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for <span title="Number of shares issued, value"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210914__20210915_ztpBS9wgpdOf" title="Stock issued during period shares new issues">50,000,000</span></span> shares at a price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20210915_zmpL8JUgtESj" title="Share price">0.10</span> for a maximum of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210914__20210915_z7jQ9hNh9cke" title="Number of shares issued, value">5,000,000</span>. The Company amended this and was able to raise $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220727__20220731_zgZOCiZ0GETi" title="Number of shares issued, value">1,200,000</span> in July 2022 at $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20220731_zUvzjUVmVVNl" title="Share price">0.08</span> per share (<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220727__20220731_zp8x2mKgiLHd" title="Stock issued during period shares new issues">15,000,000</span> shares) and sold <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220731_zdANplhW2rx8" title="Warrant sold during period">20,000,000</span> warrants for $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220731_zsKfGk7O2AZ6" title="Warrants outstanding">20,000</span>. An amended Regulation A+ was filed in October 2022 to raise the remaining $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueRemainingNewIssues_c20221030__20221031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPYASyJUHGV5" title="Shares issued remaining value">3,800,000</span> of the $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221030__20221031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWuc9dKdtKw5">5,000,000</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Regulation A+’s raised approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zLM7cLCt1fg5" title="Proceeds from stock offering">5,200,000</span> from the sale of shares and is using the proceeds generated as follows:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the animal therapy market:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents.</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct additional clinical studies to generate more data for the veterinary community</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidize some IsoPet<sup>® </sup>therapies, if necessary, to ensure that all viable candidates are treated.</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist new regional clinics with their license and certification training.</span></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the human market:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance the pedigree of the Quality Management System.</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting.</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials.</span></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_pn5n6_c20220101__20220930_zyhnVRQ59KFj" title="Current operation activities">2.5</span> million annually to maintain current operating activities. <span id="xdx_901_ecustom--OfferingTerm_c20220101__20220930" title="Offering term">Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet<sup>®</sup> across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States</span>. The proceeds to be raised from the recent qualified Regulation A+ will be used to continue to fund this development.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel<sup>™</sup> and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022, the Company has $<span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20220930_zsUZGC71dkkf" title="Cash on hand">1,987,732</span> cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash may not be enough to cover the fixed and variable obligations of the Company.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--UseOfEstimates_zKJTHdRBKdUd" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zti1q4fzwVx5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statement Reclassification</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zwpSklLTdthf" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash Equivalents</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zv9SeTpzRPaj" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Financial Instruments</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2022 and December 31, 2021, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“<i>ASC</i>”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_zeZq2qi3nHhl" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative Liabilities and Beneficial Conversion Feature</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“<i>ASC 815</i>”) as well as related interpretations of this standard and Accounting Standards Update 2017-11, which was adopted by the Company effective January 1, 2018. In accordance with this standard, derivative instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair values with gains or losses recognized in earnings.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zP1R4wyxJJAi" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed Assets</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $<span id="xdx_90C_eus-gaap--ProductionCosts_c20220101__20220930_zFMEJcdKHZZf" title="Production costs">2,500</span> or greater and other fixed assets with a cost of $<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentOther_iI_c20220930_zlBIOtZ1AApk" title="Other fixed assets cost">1,500</span> or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock_z8tdwgj9Xjkk" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation is computed using the straight-line method over the following estimated useful lives:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zbDKnDJ13EJ" style="display: none">SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE</span></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 86%; text-align: left">Production equipment:</td><td style="width: 2%"> </td> <td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_z93T7vVEWfs3" title="Estimated useful life of asset">3</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_zLj9a92lgxNf" title="Estimated useful life of asset">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office equipment:</td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zd9SX8RUsIqd" title="Estimated useful life of asset">2</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zH5OVtNEkLeh" title="Estimated useful life of asset">5</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and fixtures:</td><td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoFMzXgITDNi" title="Estimated useful life of asset">2</span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zA61KinaO1n5" title="Estimated useful life of asset">5</span> years</td></tr> </table> <p id="xdx_8AF_zmTle982GPQ4" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--LicenseFeesPolicyTextBlock_z9Mbo3S1Sgq5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License Fees</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. The Battelle Memorial Institute licensing contract is completed. One final payment of $<span id="xdx_90F_eus-gaap--IndefiniteLivedLicenseAgreements_iI_c20220930_zAeFuAFhhKKa" title="License fees">4,000 </span>due for 2022 and the final report are the last required actions.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zuUoXoTxvkl1" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patents and Intellectual Property</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no such capitalized costs in the nine months ended September 30, 2022 and 2021, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet<sup>®</sup> commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zIOjVFqAunS1" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue Recognition</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2014, the Financial Accounting Standards Board (“F<i>ASB</i>”) issued Accounting Standard Update (“<i>ASU</i>”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All revenue recognized in the nine months ended September 30, 2022 and 2021 relate to consulting income with respect to the IsoPet<sup>® </sup>therapies.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zicrWDoxeQ14" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss Per Share</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine months ended September 30, 2022 and 2021, the basic earnings per share equals the diluted earnings per share.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zV7Qigu6pbU5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represent common stock equivalents that could be dilutive in the future as of September 30, 2022 and December 31, 2021, which include the following:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zhFBxafIz6Tc" style="display: none">SCHEDULE OF DILUTIVE EARNINGS PER SHARE</span></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220101__20220930_zssN5TxNQHCh" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zwWEjzYdj3ug" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zb285dVJAm62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zGJTW78fyoAk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,362,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,262,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zLkc4QxUf95j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zXv5HCmtcxY2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,037,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,862,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z3GIdVH6W6qd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potential dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">87,562,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">69,287,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zWOGVlYFIC25" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTMLu5aV41y" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and Development Costs</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20220930_zGEqBsVF9lzl" title="Research and development costs">312,066</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20210930_zZB83s1iW1el">221,154</span> in research and development costs for the nine months ended September 30, 2022 and 2021, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the periods then ended.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zy5NSeRBTAJa" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advertising and Marketing Costs</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the nine months ended September 30, 2022 and 2021, the Company incurred nominal advertising and marketing costs.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zYO02RBXjREg" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contingencies</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2022 and December 31, 2021.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_z76ALMnf7E6h" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income Taxes</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the nine months ended September 30, 2022 and 2021. The Company did not have any deferred tax liability or asset on its balance sheets on September 30, 2022 and December 31, 2021.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the nine months ended September 30, 2022 and 2021, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zM3eVmlb52Tb" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based Compensation</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztV5YCMsxijj" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Accounting Pronouncements</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has determined that this pronouncement does not have a material impact on its financial statements.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<RDGL:BusinessOverviewPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_84E_ecustom--BusinessOverviewPolicyTextBlock_zVta8dqAzir5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Overview</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“<i>SMSC</i>”). On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation, and on December 28, 2017, the Company began operating as Vivos Inc. The Company has authorized capital of <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20220930_zrLjeHVtaNa3" title="Common stock, shares authorized">950,000,000</span> shares of common stock, $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220930_zrwN4Adrqxob" title="Common stock, par value">0.001</span> par value per share, and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20220930_z6EpMe68BHs" title="Preferred stock, shares authorized">20,000,000</span> shares of preferred stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220930_zXTVpGvHWTvk" title="Preferred stock, par value">0.001</span> par value per share.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.”</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel<sup>™</sup>, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel <sup>™</sup>should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. Additionally, after a legal review, the Company believes that the device classification obtained from the Food and Drug Administration (“<i>FDA</i>”) Center for Veterinary Medicine is not limited to canine and feline sarcomas, but rather may be extended to a much broader population of veterinary cancers, including all or most solid tumors in animals. We expect the result of such classification and label review will be that no additional regulatory approvals are necessary for the use of IsoPet<sup>® </sup>for the treatment of solid tumors in animals. The FDA does not have premarket authority over devices with a veterinary classification, and the manufacturers are responsible for assuring that the product is safe, effective, properly labeled, and otherwise in compliance with all applicable laws and regulations.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the FDA’s recommendation, RadioGel<sup>™</sup> will be marketed as “IsoPet<sup>®</sup>” for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet<sup>®</sup>” name. IsoPet<sup>® </sup>and RadioGel<sup>™</sup> are used synonymously throughout this document. The only distinction between IsoPet<sup>® </sup>and RadioGel<sup>™</sup> is the FDA’s recommendation that we use “IsoPet<sup>®</sup>” for veterinarian usage, and reserve “RadioGel<sup>™” </sup>for human therapy. Based on these developments, the Company has shifted its primary focus to the development and marketing of Isopet<sup>®</sup> for animal therapy, through the Company’s IsoPet<sup>® </sup>Solutions division.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</RDGL:BusinessOverviewPolicyTextBlock>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 950000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2022-09-30" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2022-09-30" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zd01lZ4GBvdh" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IsoPet Solutions</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet<sup>®</sup> testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet<sup>®</sup>. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“<i>RECIST</i>”) is a set of published rules that define when tumors in cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatment. The criteria were published by an international collaboration including the European Organisation for Research and Treatment of Cancer (“EORTC”), National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet<sup>®</sup>. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet<sup>®</sup> is safe for same day therapy.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effectiveness of IsoPet<sup>®</sup> for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet<sup>®</sup> therapy and will incorporate the improvements suggested by the testing program.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel<sup>™</sup> (under the name IsoPet<sup>®</sup>) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet<sup>®</sup> Solutions division as a separate operating segment in accordance with GAAP.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing in July 2019, the Company recognized its first commercial sale of IsoPet<sup>®</sup>. A veterinarian from Alaska brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received the IsoPet<sup>®</sup> during 2019.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our plan is to incorporate the data assembled from our work with Isopet<sup>®</sup> in animal therapy to support the Company’s efforts in the development of our RadioGel<sup>™</sup> device candidate, including obtaining approval from the <i>FDA</i> to market and sell RadioGel<sup>™</sup> as a Class II medical device. RadioGel<sup>™</sup> is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel<sup>™</sup> is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, less than two microns, yttrium-90 phosphate particles (“<i>Y-90</i>”). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a <span id="xdx_906_eus-gaap--DescriptionOfCreditRiskExposure_c20220101__20220930_zSCxc5FGQU57" title="Description of risk exposure">half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company modified its Indication for Use from skin cancel to cancerous tissue or solid tumors pathologically associated with locoregional papillary thyroid carcinoma and recurrent papillary thyroid carcinoma having discernable tumors associated with metastatic lymph nodes or extranodal disease in patients who are not surgical candidates or who have declined surgery, or patients who require post-surgical remnant ablation (for example, after prior incomplete radioiodine therapy). Papillary thyroid carcinoma belongs to the general class of head and neck tumors for which tumors are accessible by intraoperative direct needle injection. The Company’s Medical Advisory Board felt that demonstrating efficacy in clinical trials was much easier with this new indication.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s lead brachytherapy products, including RadioGel<sup>™</sup>, incorporate patented technology developed for Battelle Memorial Institute (“<i>Battelle</i>”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted the Company an exclusive license to patents covering the manufacturing, processing and applications of RadioGel<sup>™</sup> (the “<i>Battelle License</i>”). This exclusive license is to terminate upon the expiration of the last patent included in this agreement (December 2022). Other intellectual property protection includes proprietary production processes and trademark protection in 17 countries.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
<us-gaap:DescriptionOfCreditRiskExposure contextRef="From2022-01-01to2022-09-30"> half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days </us-gaap:DescriptionOfCreditRiskExposure>
<RDGL:IntellectualPropertyPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_84A_ecustom--IntellectualPropertyPolicyTextBlock_zCly14OeklH9" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual Property</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our original license with Battelle National Laboratory is reached its end of life. During the past several years, in anticipation of this we have expanded our proprietary knowledge and our trademark and patent protection.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have expanded our trademark protection from RadioGel to now include IsoPet. We obtained the International Certificate of Registration for ISOPET, which is the first step to file in several countries<b>.</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received the Patent Cooperation Treaty (“PCT”) International Search Report on our patent application (No.1811.191). Seven of our claims were immediately ruled as having novelty, inventive step and industrial applicability. This gives us the basis to extend for many years the patent protection for our proprietary Yttrium-90 phosphate particles utilized in Isopet<sup>®</sup> and Radiogel™.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. We filed a <span style="background-color: white">continuation-in-part applications</span> number 1774054 in the USA to expand the claims on our particle patent. <span style="background-color: white">T</span>he US Patent office recently gave us the Notice of Allowance for our patent to produce our yttrium phosphate microparticles, <span style="background-color: white">US Patent Application Serial No: 16-459,466</span>. <span style="background-color: white">We also filed an amendment to correct the wording on our claims at make them consistent with the USE claims. Ref: 4207-0005; European Patent Application NO. 20 834 229.5; VIVOS INC; Our Ref: FS/53791.</span></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We filed a hydrogel utility patent in the USA and PCT based on the last eighteen months of development work to optimize our hydrogel component. These include reducing the polymer production time and increasing the output by a factor of three. We have also further reduced the level of trace contaminants to be well below the FDA guidelines.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are continuously improving our injection system. We completed the development of a syringe shield and vial holder. We are now testing an advanced cooling system to hold the vial and syringes. We are also testing commercially available systems for deep injections, which will be useful in treating lung and pancreatic caners. We are considering filing a provisional patent on these injection system developments.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
</RDGL:IntellectualPropertyPolicyTextBlock>
<RDGL:GoingConcernPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_842_ecustom--GoingConcernPolicyTextBlock_zTOxiqmK4r5h" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_pn5n6_c20220101__20220930_zfSiNXY1Pw94" title="Current operation activities">2.5</span> million annually to maintain current operating activities.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s stock offering under Regulation A+ was qualified by the Securities and Exchange Commission (“SEC”) on June 3, 2020. A second Regulation A+ was qualified by the SEC on September 15, 2021 to raise capital for <span title="Number of shares issued, value"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210914__20210915_ztpBS9wgpdOf" title="Stock issued during period shares new issues">50,000,000</span></span> shares at a price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20210915_zmpL8JUgtESj" title="Share price">0.10</span> for a maximum of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210914__20210915_z7jQ9hNh9cke" title="Number of shares issued, value">5,000,000</span>. The Company amended this and was able to raise $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220727__20220731_zgZOCiZ0GETi" title="Number of shares issued, value">1,200,000</span> in July 2022 at $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20220731_zUvzjUVmVVNl" title="Share price">0.08</span> per share (<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220727__20220731_zp8x2mKgiLHd" title="Stock issued during period shares new issues">15,000,000</span> shares) and sold <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220731_zdANplhW2rx8" title="Warrant sold during period">20,000,000</span> warrants for $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220731_zsKfGk7O2AZ6" title="Warrants outstanding">20,000</span>. An amended Regulation A+ was filed in October 2022 to raise the remaining $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueRemainingNewIssues_c20221030__20221031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPYASyJUHGV5" title="Shares issued remaining value">3,800,000</span> of the $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221030__20221031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWuc9dKdtKw5">5,000,000</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Regulation A+’s raised approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zLM7cLCt1fg5" title="Proceeds from stock offering">5,200,000</span> from the sale of shares and is using the proceeds generated as follows:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the animal therapy market:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fund the effort to communicate the benefits of IsoPet® to the veterinary community and the pet parents.</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct additional clinical studies to generate more data for the veterinary community</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidize some IsoPet<sup>® </sup>therapies, if necessary, to ensure that all viable candidates are treated.</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assist new regional clinics with their license and certification training.</span></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the human market:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance the pedigree of the Quality Management System.</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete the previously defined pre-clinical testing and additional testing on an animal model closely aligned with our revised indication for use. Report the results to the FDA in a pre-submission meeting.</span></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 8pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials.</span></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities. The Company may require additional funding of approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_pn5n6_c20220101__20220930_zyhnVRQ59KFj" title="Current operation activities">2.5</span> million annually to maintain current operating activities. <span id="xdx_901_ecustom--OfferingTerm_c20220101__20220930" title="Offering term">Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet<sup>®</sup> across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States</span>. The proceeds to be raised from the recent qualified Regulation A+ will be used to continue to fund this development.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or from proceeds to be raised from the recent qualified Regulation A+.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel<sup>™</sup> and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States. The Company continues their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022, the Company has $<span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20220930_zsUZGC71dkkf" title="Cash on hand">1,987,732</span> cash on hand. There are currently commitments to vendors for products and services purchased. To continue the development of the Company’s products, the current level of cash may not be enough to cover the fixed and variable obligations of the Company.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</RDGL:GoingConcernPolicyTextBlock>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2022-01-01to2022-09-30" decimals="-5" unitRef="USD"> 2500000 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-09-142021-09-15" decimals="INF" unitRef="Shares"> 50000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharePrice contextRef="AsOf2021-09-15" decimals="INF" unitRef="USDPShares"> 0.10 </us-gaap:SharePrice>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-09-142021-09-15" decimals="0" unitRef="USD"> 5000000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-272022-07-31" decimals="0" unitRef="USD"> 1200000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:SharePrice contextRef="AsOf2022-07-31" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:SharePrice>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-07-272022-07-31" decimals="INF" unitRef="Shares"> 15000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2022-07-31" decimals="0" unitRef="USD"> 20000 </us-gaap:WarrantsAndRightsOutstanding>
<RDGL:StockIssuedDuringPeriodValueRemainingNewIssues contextRef="From2022-10-302022-10-31_us-gaap_SubsequentEventMember" decimals="0" unitRef="USD"> 3800000 </RDGL:StockIssuedDuringPeriodValueRemainingNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-10-302022-10-31_us-gaap_SubsequentEventMember" decimals="0" unitRef="USD"> 5000000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2022-01-012022-09-30_srt_MaximumMember" decimals="0" unitRef="USD"> 5200000 </us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="From2022-01-01to2022-09-30" decimals="-5" unitRef="USD"> 2500000 </us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<RDGL:OfferingTerm contextRef="From2022-01-01to2022-09-30"> Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States </RDGL:OfferingTerm>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 1987732 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-09-30">
<p id="xdx_843_eus-gaap--UseOfEstimates_zKJTHdRBKdUd" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:UseOfEstimates>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2022-01-01to2022-09-30">
<p id="xdx_845_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zti1q4fzwVx5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statement Reclassification</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zwpSklLTdthf" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash Equivalents</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company occasionally maintains cash balances in excess of the FDIC insured limit. The Company does not consider this risk to be material.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-01to2022-09-30">
<p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zv9SeTpzRPaj" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Financial Instruments</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of September 30, 2022 and December 31, 2021, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“<i>ASC</i>”) Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:DerivativesPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_zeZq2qi3nHhl" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative Liabilities and Beneficial Conversion Feature</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“<i>ASC 815</i>”) as well as related interpretations of this standard and Accounting Standards Update 2017-11, which was adopted by the Company effective January 1, 2018. In accordance with this standard, derivative instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair values with gains or losses recognized in earnings.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zP1R4wyxJJAi" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fixed Assets</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $<span id="xdx_90C_eus-gaap--ProductionCosts_c20220101__20220930_zFMEJcdKHZZf" title="Production costs">2,500</span> or greater and other fixed assets with a cost of $<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentOther_iI_c20220930_zlBIOtZ1AApk" title="Other fixed assets cost">1,500</span> or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock_z8tdwgj9Xjkk" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation is computed using the straight-line method over the following estimated useful lives:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zbDKnDJ13EJ" style="display: none">SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE</span></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 86%; text-align: left">Production equipment:</td><td style="width: 2%"> </td> <td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_z93T7vVEWfs3" title="Estimated useful life of asset">3</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_zLj9a92lgxNf" title="Estimated useful life of asset">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office equipment:</td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zd9SX8RUsIqd" title="Estimated useful life of asset">2</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zH5OVtNEkLeh" title="Estimated useful life of asset">5</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and fixtures:</td><td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoFMzXgITDNi" title="Estimated useful life of asset">2</span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zA61KinaO1n5" title="Estimated useful life of asset">5</span> years</td></tr> </table> <p id="xdx_8AF_zmTle982GPQ4" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ProductionCosts contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 2500 </us-gaap:ProductionCosts>
<us-gaap:PropertyPlantAndEquipmentOther contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 1500 </us-gaap:PropertyPlantAndEquipmentOther>
<RDGL:ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_893_ecustom--ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock_z8tdwgj9Xjkk" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation is computed using the straight-line method over the following estimated useful lives:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zbDKnDJ13EJ" style="display: none">SCHEDULE OF DEPRECIATION ESTIMATED USEFUL LIFE</span></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 86%; text-align: left">Production equipment:</td><td style="width: 2%"> </td> <td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_z93T7vVEWfs3" title="Estimated useful life of asset">3</span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionEquipmentMember_zLj9a92lgxNf" title="Estimated useful life of asset">7</span> years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office equipment:</td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zd9SX8RUsIqd" title="Estimated useful life of asset">2</span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zH5OVtNEkLeh" title="Estimated useful life of asset">5</span> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and fixtures:</td><td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zoFMzXgITDNi" title="Estimated useful life of asset">2</span> to <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zA61KinaO1n5" title="Estimated useful life of asset">5</span> years</td></tr> </table>
</RDGL:ScheduleOfDepreciationEstimatedUsefulLifeTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-09-30_srt_MinimumMember_custom_ProductionEquipmentMember"> P3Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-09-30_srt_MaximumMember_custom_ProductionEquipmentMember"> P7Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-09-30_srt_MinimumMember_us-gaap_OfficeEquipmentMember"> P2Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-09-30_srt_MaximumMember_us-gaap_OfficeEquipmentMember"> P5Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-09-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember"> P2Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2022-01-012022-09-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember"> P5Y </us-gaap:PropertyPlantAndEquipmentUsefulLife>
<RDGL:LicenseFeesPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_848_ecustom--LicenseFeesPolicyTextBlock_z9Mbo3S1Sgq5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License Fees</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. The Battelle Memorial Institute licensing contract is completed. One final payment of $<span id="xdx_90F_eus-gaap--IndefiniteLivedLicenseAgreements_iI_c20220930_zAeFuAFhhKKa" title="License fees">4,000 </span>due for 2022 and the final report are the last required actions.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
</RDGL:LicenseFeesPolicyTextBlock>
<us-gaap:IndefiniteLivedLicenseAgreements contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 4000 </us-gaap:IndefiniteLivedLicenseAgreements>
<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="From2022-01-01to2022-09-30">
<p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zuUoXoTxvkl1" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patents and Intellectual Property</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no such capitalized costs in the nine months ended September 30, 2022 and 2021, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet<sup>®</sup> commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zIOjVFqAunS1" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue Recognition</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2014, the Financial Accounting Standards Board (“F<i>ASB</i>”) issued Accounting Standard Update (“<i>ASU</i>”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the updated guidance effective January 1, 2018 using the full retrospective method.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized revenue as they (i) identified the contracts with each customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All revenue recognized in the nine months ended September 30, 2022 and 2021 relate to consulting income with respect to the IsoPet<sup>® </sup>therapies.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zicrWDoxeQ14" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss Per Share</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the periods ended in the nine months ended September 30, 2022 and 2021, the basic earnings per share equals the diluted earnings per share.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zV7Qigu6pbU5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represent common stock equivalents that could be dilutive in the future as of September 30, 2022 and December 31, 2021, which include the following:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zhFBxafIz6Tc" style="display: none">SCHEDULE OF DILUTIVE EARNINGS PER SHARE</span></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220101__20220930_zssN5TxNQHCh" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zwWEjzYdj3ug" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zb285dVJAm62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zGJTW78fyoAk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,362,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,262,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zLkc4QxUf95j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zXv5HCmtcxY2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,037,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,862,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z3GIdVH6W6qd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potential dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">87,562,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">69,287,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zWOGVlYFIC25" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zV7Qigu6pbU5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represent common stock equivalents that could be dilutive in the future as of September 30, 2022 and December 31, 2021, which include the following:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zhFBxafIz6Tc" style="display: none">SCHEDULE OF DILUTIVE EARNINGS PER SHARE</span></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220101__20220930_zssN5TxNQHCh" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_zwWEjzYdj3ug" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zb285dVJAm62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">9,909,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsMember_zGJTW78fyoAk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,362,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,262,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zLkc4QxUf95j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,252,809</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zXv5HCmtcxY2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,037,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">31,862,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z3GIdVH6W6qd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potential dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">87,562,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">69,287,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember" decimals="INF" unitRef="Shares"> 9909570 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" decimals="INF" unitRef="Shares"> 9909570 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-09-30_custom_RestrictedStockUnitsMember" decimals="INF" unitRef="Shares"> 25362500 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-012021-12-31_custom_RestrictedStockUnitsMember" decimals="INF" unitRef="Shares"> 25262500 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-09-30_custom_CommonStockOptionsMember" decimals="INF" unitRef="Shares"> 2252809 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-012021-12-31_custom_CommonStockOptionsMember" decimals="INF" unitRef="Shares"> 2252809 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-09-30_custom_CommonStockWarrantsMember" decimals="INF" unitRef="Shares"> 50037500 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantsMember" decimals="INF" unitRef="Shares"> 31862500 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-01to2022-09-30" decimals="INF" unitRef="Shares"> 87562379 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2021-01-012021-12-31" decimals="INF" unitRef="Shares"> 69287379 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-09-30">
<p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zTMLu5aV41y" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and Development Costs</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20220930_zGEqBsVF9lzl" title="Research and development costs">312,066</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20210930_zZB83s1iW1el">221,154</span> in research and development costs for the nine months ended September 30, 2022 and 2021, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the periods then ended.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 312066 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 221154 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zy5NSeRBTAJa" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advertising and Marketing Costs</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. During the nine months ended September 30, 2022 and 2021, the Company incurred nominal advertising and marketing costs.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:AdvertisingCostsPolicyTextBlock>
<us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_84E_eus-gaap--CommitmentsAndContingenciesPolicyTextBlock_zYO02RBXjREg" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contingencies</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of September 30, 2022 and December 31, 2021.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_z76ALMnf7E6h" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income Taxes</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the nine months ended September 30, 2022 and 2021. The Company did not have any deferred tax liability or asset on its balance sheets on September 30, 2022 and December 31, 2021.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the nine months ended September 30, 2022 and 2021, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-01to2022-09-30">
<p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zM3eVmlb52Tb" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based Compensation</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs under FASB ASC Topic 718, Compensation – Stock Compensation and ASU 2018-07. Companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztV5YCMsxijj" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Accounting Pronouncements</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40), Accounting for Convertible Instruments and Contract’s in an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU simplifies the diluted net income per share calculation in certain areas. The ASU is effective for annual and interim periods beginning after December 31, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has determined that this pronouncement does not have a material impact on its financial statements.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z2DAThEgasEk" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2: <span id="xdx_82E_z6LETVM5rz89">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Party Notes Payable</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The $<span id="xdx_90D_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231_zirRnrCve2B" title="Notes payable related party, outstanding balance"><span id="xdx_90C_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20201231_zdy99bqG4Mqh" title="Notes payable related party, outstanding balance">237,000</span></span> in related party notes payable that were outstanding during 2020 and 2021 were either repaid or converted in December 2021. There are <span id="xdx_90C_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_do_c20220930_zTdPkV9cU9hd" title="Notes payable related party, outstanding balance">no</span> outstanding related party notes payable as of September 30, 2022.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Party Payables</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, the Company converted the $<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRifcanhM7ja" title="Related party payable conversion">32,110</span> in related party payables into <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Conversion of common stock, shares">401,373</span> shares of common stock. There are <span id="xdx_909_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_do_c20220930_zxM7jKqB88Gd" title="Accounts payable, related parties, current">no</span> remaining related party payables as of September 30, 2022.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred and Common Shares Issued to Officers and Directors</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2021, the Company’s Chief Executive Officer exercised<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210601__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zJqYLpCXWlN8" title="Stock options exercised shares"> 2,500,000</span> stock options for a value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210601__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zXZHVdsJb6f6" title="Stock options exercised value">60,000</span> that was paid through the cancelation of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210601__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH1N5UstJe33" title="Cancelation shares">375,000 </span>common shares and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210601__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zr2oY9IRktW4" title="Cancelation shares">100,000</span> Series A Convertible Preferred shares. The Chief Executive Officer in May 2021 rescinded <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesStockOptionsRescinded_c20210501__20210531__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z1NUtRWMHcfc" title="Rescinded shares">8,120,152</span> stock options and in June 2021 rescinded <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesStockOptionsRescinded_c20210601__20210630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zMfWgbH1pGW5" title="Rescinded shares">16,000,000</span> stock options. In September 2021, the Chief Executive Officer exercised <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20210930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zqTclgczypOc">150,000</span> warrants in a cashless exercise into <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20210901__20210930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJ3YVRQ3GVh">91,304</span> shares of common stock. In March 2022, the Chief Executive Officer exercised <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zvjeCKJMxwff" title="Warrants exercised shares">75,000</span> warrants in a cashless exercise into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20220301__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z575xWKLgE2" title="Conversion of stock">22,266</span> shares of common stock, and was issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220301__20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ8gB5MQHWQj" title="Stock issued for services, shares">76,250</span> shares of common stock valued at $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_za6Z1sZ5Xtja" title="Stock issued for services, value">4,880</span> for services rendered.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 237000 </us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 237000 </us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 0 </us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 32110 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 401373 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 0 </us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2021-06-012021-06-30_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 2500000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2021-06-012021-06-30_srt_ChiefExecutiveOfficerMember" decimals="0" unitRef="USD"> 60000 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2021-06-012021-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 375000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2021-06-012021-06-30_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 100000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<RDGL:StockIssuedDuringPeriodSharesStockOptionsRescinded contextRef="From2021-05-012021-05-31_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 8120152 </RDGL:StockIssuedDuringPeriodSharesStockOptionsRescinded>
<RDGL:StockIssuedDuringPeriodSharesStockOptionsRescinded contextRef="From2021-06-012021-06-30_srt_ChiefExecutiveOfficerMember30986031" decimals="INF" unitRef="Shares"> 16000000 </RDGL:StockIssuedDuringPeriodSharesStockOptionsRescinded>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2021-09-30_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 150000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="From2021-09-012021-09-30_srt_ChiefExecutiveOfficerMember_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 91304 </us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2022-03-31_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 75000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="From2022-03-012022-03-31_srt_ChiefExecutiveOfficerMember_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 22266 </us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2022-03-012022-03-31_srt_ChiefExecutiveOfficerMember_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 76250 </us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-03-012022-03-31_srt_ChiefExecutiveOfficerMember_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 4880 </us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zw6cxeYAOBpb" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3: <span id="xdx_826_zYriTdyOSY1b">CONVERTIBLE NOTES PAYABLE</span></b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022 and December 31, 2021, there remains <span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_do_c20220930__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zpqwn1v2Bsf3" title="Convertible notes payable"><span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_do_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zOUPP8OtdpXg" title="Outstanding balances">no</span></span> outstanding balances in the convertible notes payable. All prior convertible notes had been either repaid or converted in 2021.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2022-09-30_us-gaap_ConvertibleNotesPayableMember" decimals="0" unitRef="USD"> 0 </us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" decimals="0" unitRef="USD"> 0 </us-gaap:DebtInstrumentFaceAmount>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zNFpGGcVqCQe" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4: <span id="xdx_82C_zzDpz79Qlezj">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zTZqo3OHTSHl"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20220930_zdSGhe044G8l" title="Common stock, shares authorized">950,000,000</span></span> shares of common stock authorized, with a par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_zY10kdESNvg8"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220930_zpyazk7QkST" title="Common stock, par value">0.001</span></span>, and as of September 30, 2022 and December 31, 2021, the Company has <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20220930_zk9gSNVZFXWf"><span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20220930_znXfAkeOQxT1" title="Common stock, shares issued">359,891,255</span></span> and <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zwDC8L9fvcEc" title="Common stock, shares outstanding"><span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20211231_z6pBsNQ6Gqg2" title="Common stock, shares issued">343,530,678</span></span> shares issued and outstanding, respectively.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022 and December 31, 2021, the Company has <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20220930_zKgHov62XGW6" title="Preferred stock shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zhNbtdOcujJj" title="Preferred stock shares authorized">20,000,000</span></span> shares of Preferred stock authorized with a par value of $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220930_z7AKmmvOSihj" title="Preferred stock, par value"><span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zDQXUadBf7Gf" title="Preferred stock, par value">0.001</span></span>. The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20181008__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zTAJHhw0EYEk" title="Preferred stock, par value">0.001</span> per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series B Convertible Preferred Stock,” consisting of Five Million (<span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20181008__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zwf1FY5A6oU7" title="Preferred stock, shares authorized">5,000,000</span>) shares.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2019 the Company created out of the shares of Preferred Stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zEITwxJOa3pa" title="Preferred stock, par value">0.001</span> per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series C Convertible Preferred Stock,” consisting of Five Million (<span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20190327__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zYBdSs2mtkk5" title="Preferred stock, shares authorized">5,000,000</span>) shares.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series A Convertible Preferred Stock (“Series A Convertible Preferred”)</i></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pn5n6_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zCTPozEuNnHh" title="Preferred stock shares authorized">2.5</span> million shares of our preferred stock as Series A Convertible Preferred. Effective March 31, 2016, the Company amended the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred of the Registrant, increasing the maximum number of shares of Series A Convertible Preferred from <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20160331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_z6DcazX7fod9" title="Preferred stock, shares authorized">2,500,000</span> shares to <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20160331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zJoINkRmWeUe" title="Preferred stock, shares authorized">5,000,000</span> shares. The following summarizes the current rights and preferences of the Series A Convertible Preferred:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation Preference</span>. The Series A Convertible Preferred has a liquidation preference of $<span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zAk0I2kVqHCi" title="Preferred stock, liquidation preference per share">5.00</span> per share.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span>. Shares of Series A Convertible Preferred do not have any separate dividend rights.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion</span>. Subject to certain limitations set forth in the Series A Certificate of Designation, each share of Series A Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “<i>Series A Conversion Shares</i>”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series A Certificate of Designation), currently $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_ztLokdxAEDye" title="Conversion price, per share">4.00</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20150601__20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zqkRVTRgXNn2" title="Gross proceeds from preferred stock">5.0</span> million, all issued and outstanding shares of Series A Convertible Preferred at that time will automatically convert into Series A Conversion Shares.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Redemption</span>. <span id="xdx_901_eus-gaap--PreferredStockVotingRights_c20150601__20150630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zjdjk9CQzBja">Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting Rights</span>. Holders of Series A Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of five (5) votes for every Series A Conversion Share issuable upon conversion of such holder’s outstanding shares of Series A Convertible Preferred. However, the Series A Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation</span>. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “<i>Liquidation</i>”), the holders of Series A Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series A Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series A Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certain Price and Share Adjustments</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <i>Stock Dividends and Stock Splits</i>. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <i>Merger or Reorganization</i>. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series A Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series A Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2021, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20210601__20210630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zdYu1LuovJH3" title="Cancellation of shares">100,000</span> shares of Series A Convertible Preferred were canceled as partial payment for the exercise of stock options by the Chief Executive Officer.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series B Convertible Preferred Stock (“Series B Convertible Preferred”)</i></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pn5n6_c20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zZfFHe4BTsij" title="Preferred stock shares authorized">5.0</span> million shares of our preferred stock as Series B Convertible Preferred. The following summarizes the current rights and preferences of the Series B Convertible Preferred:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation Preference</span>. The Series B Convertible Preferred has a liquidation preference of $<span id="xdx_90D_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zsPZFiJBea9j" title="Preferred stock, liquidation preference per share">1.00</span> per share.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span>. Shares of Series B Convertible Preferred do not have any separate dividend rights.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion</span>. Subject to certain limitations set forth in the Series B Certificate of Designation, each share of Series B Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “<i>Series B Conversion Shares</i>”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series B Certificate of Designation), currently $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zVxivtPwt6nh" title="Conversion price per share">0.08</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Redemption</span>. <span id="xdx_90E_eus-gaap--PreferredStockVotingRights_c20181001__20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zyAcTRcxsxGi">Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to <span id="xdx_908_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_uPure_c20181001__20181031__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zz1GZhj3FfY9">100</span>% of the Liquidation Preference</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting Rights</span>. Holders of Series B Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of two (2) votes for every Series B Conversion Share issuable upon conversion of such holder’s outstanding shares of Series B Convertible Preferred. However, the Series B Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series A Convertible Preferred.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation</span>. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “<i>Liquidation</i>”), the holders of Series B Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series B Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series B Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certain Price and Share Adjustments</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <i>Stock Dividends and Stock Splits</i>. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <i>Merger or Reorganization</i>. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series B Convertible Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series B Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20211201__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zblus1MKaf09" title="Conversion of preferred stock into common stock">236,290</span> Series B Convertible Preferred shares were converted into <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20211201__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxbr9LBA3ibg" title="Conversion of preferred stock into common stock">2,953,625</span> shares of common stock.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series C Convertible Preferred Stock (“Series C Convertible Preferred”)</i></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2019, the Series C Certificate of Designation was filed with the Delaware Secretary of State to designate <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pn5n6_c20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zGwEyuIaPUec" title="Preferred stock shares authorized">5.0</span> million shares of our preferred stock as Series C Convertible Preferred. The following summarizes the current rights and preferences of the Series C Convertible Preferred:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation Preference</span>. The Series C Convertible Preferred has a liquidation preference of $<span id="xdx_90B_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z096xLURptC1" title="Preferred stock, liquidation preference per share">1.00</span> per share.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span>. Shares of Series C Convertible Preferred do not have any separate dividend rights.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion</span>. Subject to certain limitations set forth in the Series C Certificate of Designation, each share of Series C Convertible Preferred is convertible, at the option of the holder, into that number of shares of common stock (the “<i>Series C Conversion Shares</i>”) equal to the liquidation preference thereof, divided by Conversion Price (as such term is defined in the Series C Certificate of Designation), currently $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zyqHeiqL9Sjb" title="Conversion price per share">0.08</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series C Convertible Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of common stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of common stock by a sufficient amount to permit the conversion of all Series C Convertible Preferred into shares of common stock (“<i>Authorized Share Approval</i>”) (such date, the “<i>Initial Convertibility Date</i>”), each share of Series C Convertible Preferred shall be convertible into validly issued, fully paid and non-assessable shares of Common Stock on the terms and conditions set forth in the Series C Certificate of Designation under the definition “<i>Conversion Rights</i>”.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Redemption</span>. <span id="xdx_903_eus-gaap--PreferredStockVotingRights_c20190301__20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zIBrzgJB91Qi" title="Voting percentage">Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to <span id="xdx_901_eus-gaap--DebtInstrumentRedemptionPricePercentage_pid_dp_c20190301__20190331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zXqSCNfQF9K9" title="Redemption percentage">100</span>% of the Liquidation Preference</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting Rights</span>. Holders of Series C Convertible Preferred are entitled to vote on all matters, together with the holders of common stock, and have the equivalent of thirty-two (32) votes for every Series C Conversion Share issuable upon conversion of such holder’s outstanding shares of Series C Convertible Preferred. However, the Series C Conversion Shares, when issued, will have all the same voting rights as other issued and outstanding common stock of the Company, and none of the rights of the Series C Convertible Preferred.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation</span>. Upon any liquidation, dissolution, or winding-up of the Company, whether voluntary or involuntary (a “<i>Liquidation</i>”), the holders of Series C Convertible Preferred shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to the liquidation preference of the Series C Convertible Preferred before any distribution or payment shall be made to the holders of any junior securities, and if the assets of the Company is insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of the Series C Convertible Preferred shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certain Price and Share Adjustments</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <i>Stock Dividends and Stock Splits</i>. If the Company (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents; (ii) subdivides outstanding shares of common stock into a larger number of shares; (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares; or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price shall be adjusted accordingly.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <i>Merger or Reorganization</i>. If the Company is involved in any reorganization, recapitalization, reclassification, consolidation or merger in which the Common Stock is converted into or exchanged for securities, cash or other property than each share of Series C Convertible Preferred shall be convertible into the kind and amount of securities, cash or other property that a holder of the number of shares of common stock issuable upon conversion of one share of Series C Convertible Preferred prior to any such merger or reorganization would have been entitled to receive pursuant to such transaction.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common and Preferred Stock Issuances - 2022</i></b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the Company issued<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlLVzR4HG6Pb" title="Common stock issued, shares"> 299,577</span> shares of common stock in the cashless exercise of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR4B7X5xtGT4" title="Warrants exercise shares">825,000</span> warrants, and issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z8pDoI8C1gPa" title="Shares issued for services">76,250</span> shares of common stock to its CEO for services rendered valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5vjhCPmYOJl" title="Shares issued for services, value">4,880</span>. In June 2022, there was a fractional adjustment recorded for <span id="xdx_902_ecustom--FunctionalAdjustmentShares_pid_c20220602__20220630_zpVbnSyHDDd1" title="Functional adjustment, shares">90</span> shares.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2022, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220705__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXHE1hZxBNhj" title="Number of shares sold">15,000,000</span> shares under the Regulation A+ at $<span id="xdx_903_eus-gaap--SharePrice_iI_c20220707_zjb92n2A6Wuk" title="Share price">0.08</span> for $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20220705__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGZHcoESaeX5" title="Number of shares issued, value">1,200,000</span>, and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy7DzePI1BJ6">20,000,000</span> warrants (<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220705__20220707__us-gaap--AwardDateAxis__custom--JuneTwoThousandTwentyFiveMember_zaSBMy6RuqP1" title="Number of shares issued">15,000,000</span> at $<span id="xdx_909_eus-gaap--SharePrice_iI_c20220707__us-gaap--AwardDateAxis__custom--JuneTwoThousandTwentyFiveMember_zeKEI4AehzM" title="Share price">0.08</span> expiring June 2025 and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220705__20220707__us-gaap--AwardDateAxis__custom--DecemberTwoThousandTwentyTwoMember_zHqF23t2Nlse" title="Number of shares issued">5,000,000</span> at $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20220707__us-gaap--AwardDateAxis__custom--DecemberTwoThousandTwentyTwoMember_z7zdAbyTcqyf" title="Share price">0.01</span> expiring December 2022) for $<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220707_zcf1B6pi7Fz5" title="Warrants outstanding">20,000</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220930__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zzLtQhgnCJHl" title="Number of shares issued">984,840</span> shares valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zFqFKfMjWhf4" title="Number of shares issued, value">49,242</span> in settlement of accounts payable.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common and Preferred Stock Issuances - 2021</i></b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210131__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zf9O8pmZphB" title="Number of shares issued">384,445</span> shares of common stock in a settlement of accounts payable valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210131__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zVWvr9cYBw7l" title="Number of shares issued, value">50,000</span>. In May 2021, the Company issued<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210501__20210531__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zIhF7JcEqZ6f" title="Number of shares issued"> 519,480</span> shares of common stock in a settlement of accounts payable valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210501__20210531__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--AccountsPayableMember_zRu1d7Kcx6S3" title="Number of shares issued, value">40,000</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company issued <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHkMJRpSqua9" title="Debt conversion, share">1,259,250</span> shares of common stock in conversion of a note payable and accrued interest totaling $<span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20210101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn5gGZ5DvRv2" title="Debt instrument, accrued interest">50,370</span>. The conversion resulted in a loss on conversion of $<span id="xdx_901_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210101__20210930_zU1BQmqITWra" title="Gain (Loss) on Extinguishment of Debt">176,295</span> that is reflected in the Condensed Statement of Operations for the nine months ended September 30, 2021.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210301__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAgpYsie4LCh" title="Number of shares issued">22,500,000</span> shares of common stock along with <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlsQiNV3alEl" title="Number of warrants issued">11,237,500</span> warrants under the Regulation A+ for cash proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210301__20210331_zq0pOBHVgUoa" title="Proceeds from issuance of common stock">1,800,000</span> for the common stock and the warrants were purchased for $<span id="xdx_90C_ecustom--WarrantPurchase_iI_c20210331_zVPk23LhzxWf" title="Warrant purchase">11,238</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the nine months ended September 30, 2021, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV1SiQnAGtKf" title="Number of shares issued">4,708,623</span> shares of common stock in the cashless exercise of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6IEx2OvDZ3f" title="Number of warrant exercised">7,230,000</span> warrants; and issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDclBwVy9pEa" title="Stock issued during period shares other">2,125,000</span> shares of common stock in the exercise of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoUpCsIwjRPd" title="Stock issued during period shares stock options exercised">2,500,000</span> stock options and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2F8D9t3ZPth" title="Stock issued during period shares new issues">100,000</span> Series A preferred shares.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 950000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 950000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2022-09-30" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 359891255 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 359891255 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 343530678 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 343530678 </us-gaap:CommonStockSharesIssued>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2022-09-30" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-10-08_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-10-08_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-03-27_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-03-27_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2015-06-30_custom_SeriesAConvertiblePreferredStockMember" decimals="-5" unitRef="Shares"> 2500000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-03-31_custom_SeriesAConvertiblePreferredStockMember_srt_MinimumMember" decimals="INF" unitRef="Shares"> 2500000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-03-31_custom_SeriesAConvertiblePreferredStockMember_srt_MaximumMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockLiquidationPreference contextRef="AsOf2015-06-30_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 5.00 </us-gaap:PreferredStockLiquidationPreference>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2015-06-30_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 4.00 </us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2015-06-012015-06-30_custom_SeriesAConvertiblePreferredStockMember" decimals="-5" unitRef="USD"> 5000000.0 </us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:PreferredStockVotingRights contextRef="From2015-06-012015-06-30_custom_SeriesAConvertiblePreferredStockMember"> Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference </us-gaap:PreferredStockVotingRights>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2021-06-012021-06-30_srt_ChiefExecutiveOfficerMember_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 100000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-10-31_custom_SeriesBConvertiblePreferredStockMember" decimals="-5" unitRef="Shares"> 5000000.0 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockLiquidationPreference contextRef="AsOf2018-10-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 1.00 </us-gaap:PreferredStockLiquidationPreference>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2018-10-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:PreferredStockVotingRights contextRef="From2018-10-012018-10-31_custom_SeriesBConvertiblePreferredStockMember"> Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference </us-gaap:PreferredStockVotingRights>
<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="From2018-10-012018-10-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Pure"> 1 </us-gaap:DebtInstrumentRedemptionPricePercentage>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-12-012021-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 236290 </us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-12-012021-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 2953625 </us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-03-31_custom_SeriesCConvertiblePreferredStockMember" decimals="-5" unitRef="Shares"> 5000000.0 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockLiquidationPreference contextRef="AsOf2019-03-31_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 1.00 </us-gaap:PreferredStockLiquidationPreference>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2019-03-31_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:PreferredStockVotingRights contextRef="From2019-03-012019-03-31_custom_SeriesCConvertiblePreferredStockMember"> Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series C Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference </us-gaap:PreferredStockVotingRights>
<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="From2019-03-012019-03-31_custom_SeriesCConvertiblePreferredStockMember" decimals="INF" unitRef="Pure"> 1 </us-gaap:DebtInstrumentRedemptionPricePercentage>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-03-012022-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 299577 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2022-03-012022-03-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 825000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2022-03-012022-03-31_srt_ChiefExecutiveOfficerMember_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 76250 </us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2022-03-012022-03-31_srt_ChiefExecutiveOfficerMember_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 4880 </us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<RDGL:FunctionalAdjustmentShares contextRef="From2022-06-022022-06-30" decimals="INF" unitRef="Shares"> 90 </RDGL:FunctionalAdjustmentShares>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-07-052022-07-07_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 15000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharePrice contextRef="AsOf2022-07-07" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:SharePrice>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-052022-07-07_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 1200000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2022-07-07_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-07-052022-07-07_custom_JuneTwoThousandTwentyFiveMember" decimals="INF" unitRef="Shares"> 15000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharePrice contextRef="AsOf2022-07-07_custom_JuneTwoThousandTwentyFiveMember" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:SharePrice>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-07-052022-07-07_custom_DecemberTwoThousandTwentyTwoMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharePrice contextRef="AsOf2022-07-07_custom_DecemberTwoThousandTwentyTwoMember" decimals="INF" unitRef="USDPShares"> 0.01 </us-gaap:SharePrice>
<us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2022-07-07" decimals="0" unitRef="USD"> 20000 </us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-01-012022-09-30_us-gaap_AccountsPayableMember" decimals="INF" unitRef="Shares"> 984840 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-01-012022-09-30_us-gaap_AccountsPayableMember" decimals="0" unitRef="USD"> 49242 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-012021-01-31_us-gaap_AccountsPayableMember" decimals="INF" unitRef="Shares"> 384445 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-01-012021-01-31_us-gaap_AccountsPayableMember" decimals="0" unitRef="USD"> 50000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-05-012021-05-31_us-gaap_AccountsPayableMember" decimals="INF" unitRef="Shares"> 519480 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2021-05-012021-05-31_us-gaap_AccountsPayableMember" decimals="0" unitRef="USD"> 40000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2021-01-012021-01-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 1259250 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="From2021-01-012021-01-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 50370 </us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> -176295 </us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-03-012021-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 22500000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 11237500 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2021-03-012021-03-31" decimals="0" unitRef="USD"> 1800000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<RDGL:WarrantPurchase contextRef="AsOf2021-03-31" decimals="0" unitRef="USD"> 11238 </RDGL:WarrantPurchase>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 4708623 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2021-01-012021-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 7230000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 2125000 </us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 2500000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-012021-09-30_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 100000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_808_ecustom--CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock_ziyPHTqsFvSk" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5: <span id="xdx_828_zMABEqzNklPb">COMMON STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS</span></b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Options</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zV63mdIggoSg" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock options:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_z2QeqmsOmya4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF CHANGES IN STOCK OPTION</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per Share</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per Share</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zkQ97FMTnJPb" style="width: 6%; text-align: right" title="Number of Options Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,885,461</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_z3Pz91Mxuu5h" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_ztK2oNqDawN4" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zwzx4kIr0c2b" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning">5.57</span> years</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_zISJgGmv2t6e" style="width: 6%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,661,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20210101__20211231_zPQVrDpwyf8g" style="width: 6%; text-align: right" title="custom:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231_zzH0l6AzeeTg" style="text-align: right" title="Number of Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zWobyjZKETo3" style="text-align: right" title="Exercise Price Per Share granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20210101__20211231_zKETw9UVyPcj" style="text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20211231_zWYieVYOjGii" style="text-align: right" title="Number of Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zt301NbhGgP7" style="text-align: right" title="Exercise Price Per Share exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20210101__20211231_z0tR2nUv0CXe" style="text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options expired</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20210101__20211231_zJJPFWreJZ61" style="text-align: right" title="Number of Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24,132,652</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zMogXLrt6n6b" style="text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20210101__20211231_zvy7CmWLPXYa" style="text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930_zbBenj66uwaa" style="text-align: right" title="Number of Options Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zUNpBGrc0nlj" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_z7yCLHDg9xm5" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z31TEPNICkci" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning">7.70</span> years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20220930_zq7zYlBYiSqh" style="text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20220101__20220930_zrZiomWQFHF6" style="text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20220930_zyLeToW3IKh5" style="text-align: right" title="Number of Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930_zr7pVPXC6in6" style="text-align: right" title="Exercise Price Per Share granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1204">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20220101__20220930_z7NioRur9UL2" style="text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220930_zq1GGIGcmJGk" style="text-align: right" title="Number of Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1208">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930_zI8sFYG7nF3c" style="text-align: right" title="Exercise Price Per Share exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20220101__20220930_z5KrdBPI0SAe" style="text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1212">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options expired/canceled</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20220930_zyMA7rl0ayCl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1214">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930_z9A1xh7BqZgf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20220101__20220930_zJbFXmIFgXG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220930_z9OAVsUVS9da" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zMyps7093AE5" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_z2TuKMPD6lo5">0.04</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930_zfA2vBXjnLsg" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Ending">6.95</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20220930_zw1fGaPDEDre" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,901</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iE_c20220101__20220930_ztfGzd93JXBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20220930_z5qFekDsuHY7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zY94ykyEmQah" title="Exercise Price Per Share Exercisable">0.024</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zEDHegetWTS3" title="Exercise Price Per Share Exercisable">0.04</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930_zG3LmWaMuFrk" title="Weighted Average Remaining Contractual Life (in years) Exercisable">6.95</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20220930_zi6l6YpnKhf5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,901</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares_iE_c20220101__20220930_zj8m3o5sL6Bg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zIinUymyYQTe" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company’s CEO exercised <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z2sm9E2TWMV7" title="Number of shares exercised">2,500,000</span> stock options, and rescinded <span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesStockOptionsRescinded_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcuytn0DaKd" title="Number of stock option rescinded">24,120,152</span>, stock options. In addition, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zN6l7JT7b74f" title="Number of options expired">12,500</span> options expired.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022 and 2021, the Company recognized $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPG56djgnshj" title="Stock based compensation">0</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_za0WeLQ1XBT1" title="Stock based compensation">0</span>, respectively, worth of stock based compensation related to the vesting of it stock options.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Warrants</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zvw6s9PB9bHc" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock warrants:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zzoLSVxaIgf3" style="display: none">SCHEDULE OF CHANGES IN STOCK WARRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted<br/> Average </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted<br/> Average</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number Of<br/></p> <p style="margin-top: 0; margin-bottom: 0">Shares</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Exercise</p> <p style="margin-top: 0; margin-bottom: 0">Price Per</p> <p style="margin-top: 0; margin-bottom: 0">Share</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; font-size: 8pt; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining Contractual</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life</span></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 8pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate<br/></p> <p style="margin-top: 0; margin-bottom: 0">Intrinsic</p> <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Exercise<br/></p> <p style="margin-top: 0; margin-bottom: 0">Price Per</p> <p style="margin-top: 0; margin-bottom: 0">Share</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%">Balance at December 31, 2020</td><td style="width: 1%"> </td> <td style="width: 2%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNcdvUCWnBs1" style="width: 8%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">32,064,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z5njX0lhyaaa" title="Exercise Price Per Share Warrants Outstanding Beginning">0.04</span>-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise Price Per Share Warrants Outstanding Ending">80.00</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5jybTMi3At9" title="Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning">1.65</span> years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZV0lYigc5rd" style="width: 8%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">1,614,567</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ExercisePriceMinimum_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpgEyizuaKP5" style="width: 8%; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning">0.06</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztWikh6uFKMg" style="text-align: right" title="Number of Shares, Warrants granted">11,237,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4HFiJapn6C9" title="Exercise Price Per Share Warrants granted">0.10</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeEwFWipfghf" style="text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVj5Lofdf7A7" style="text-align: right" title="Number of Shares, Warrants exercised">(10,730,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBkwl09KF4cd" style="text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants expired/cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZRFEcfqQfqi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants expired/cancelled">(709,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkaB4oYePS3e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1279">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwEqzjVZLT3g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">31,862,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zaAlvwc7rTN9" title="Exercise Price Per Share Warrants Outstanding Beginning">0.04</span>-<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zG1ZkFwToyll" title="Exercise Price Per Share Warrants Outstanding Beginning">0.10</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziiKQ9zrkPMa" title="Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning">1.02</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVFoIBZVrazk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">538,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ExercisePriceMinimum_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z44yHMlfeAPh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zW9S6HacOyx9" style="text-align: right" title="Number of Shares, Warrants granted">20,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJo8o5JgIt7g" style="text-align: right" title="Exercise Price Per Share Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1295">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zavBrZDRNz34" style="text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOIDkymvqVB9" style="text-align: right" title="Number of Shares, Warrants exercised">(825,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVHFgMKctHyj" style="text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants expired/cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4xG20NHO0l3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants expired/cancelled">(1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrrwB4XgXowg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWlwbTvqEeQ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">50,037,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zI6yjoDGglO8" title="Exercise Price Per Share Warrants Outstanding Ending">0.04</span>-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_ztLZJYhFDfb2" title="Exercise Price Per Share Warrants Outstanding Ending">0.10</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zun3KHhqbko5" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">1.04</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1eBPpnwDf7a" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending">205,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ExercisePriceMinimum_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqhG43lGm6qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Ending">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z48ycAmwbaFd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable Ending">50,037,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zxIl1eK89Yb1" title="Exercise Price Per Share Exercisable">0.04</span>-<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSBhmpZHz8Pf" title="Exercise Price Per Share Exercisable">0.10</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq576MYfwbL5" title="Weighted Average Remaining Contractual Life Warrants Exercisable">1.04</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zh35XsHIZh52" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable">205,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQYMMsgRCuJe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table> <p id="xdx_8A9_zuNbjKkAbVUc" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zAzMG62l64N" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zvyB1NeI56o9" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-size: 8pt"> </td> <td colspan="2" style="font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p></td><td style="font-size: 8pt"> </td><td style="font-size: 8pt"> </td> <td colspan="2" style="font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p></td><td style="font-size: 8pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-size: 8pt; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 8pt"> </td><td style="font-size: 8pt; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 8pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zzZCuVzF1GI">.5</span> – <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zqqxhkRcX6Hg">3</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zsYh3ExgYWag" title="Expected term">2</span> - <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zDKLJcNw0mHg" title="Expected term">5</span> years</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20220930_zuIpGYEV9zP4" style="width: 14%; text-align: right" title="Expected volatility">66</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zL0XrJBtzrqi" title="Expected volatility">109</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zG7FuuCoN5qd" title="Expected volatility">147</span></span></td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220930_z59FVUTJaaJh" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231_zhglHlLGtX69" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20220930_zT65hLhMc1q1" style="text-align: right" title="Risk-free interest rate">3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zUx8Waljk9Wf" title="Risk-free interest rate">0.20</span> - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zkFkCICtqZAg" title="Risk-free interest rate">0.58</span></span></td><td style="text-align: left">%</td> </tr> </table> <p id="xdx_8A3_zrRrFWt0THSh" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between January 8, 2021 and January 29, 2021, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210108__20210129__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zasEyNnP3Iz8" title="Number of shares issued">3,870,428</span> shares of common stock in the cashless exercise of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210108__20210129__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoMWb46MK5G5" title="Number of warrant exercised">5,430,000</span> warrants.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021 the Company sold <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ6YBng9cpz" title="Number of warrants issued">11,237,500</span> warrants for $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_c20210301__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrK7RAbnIy2c" title="Proceeds from issuance of warrant">11,238</span>. These warrants have a <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKHOsifZVQBl" title="Warrants and rights outstanding term::XDX::P2Y"><span style="-sec-ix-hidden: xdx2ixbrl1363">two-year term</span></span> and have an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoTXbHlcqe2l" title="Warrants exercise price">0.10</span> per share.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From July 9 through September 24, 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210709__20210924__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2YFkzVltTX7" title="Number of shares issued">838,195</span> shares of common stock in the cashless exercise of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210709__20210924__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhpwNWxym2l3" title="Number of warrant exercised">1,800,000</span> warrants.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20211001__20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPg2S09fCk4l" title="Number of shares issued">2,005,693</span> shares of common stock in the cashless exercise of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20211001__20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuUdzaUGGf0h" title="Number of warrant exercised">3,500,000</span> warrants.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022 the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIJMq3NM9sgi" title="Number of shares issued">299,577</span> shares of common stock in the cashless exercise of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220301__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPs3bQBHYnza" title="Number of warrant exercised">825,000</span> warrants. In June 2022, <span id="xdx_90B_ecustom--WarrantsExpired_pid_c20220529__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ0lABNFB22i" title="Warrants expired">1,000,000</span> warrants expired.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2022, the Company sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220705__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQgpaCPsmyZ6" title="Number of shares sold">15,000,000</span> shares under the Regulation A+ at $<span id="xdx_900_eus-gaap--SharePrice_iI_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0aA2BTKzBP7" title="Share price">0.08</span> for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20220705__20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoQ1ISu0A4l4" title="Number of shares issued, value">1,200,000</span>, and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMmgELgpdcu9">20,000,000</span> warrants (<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220705__20220707__us-gaap--AwardDateAxis__custom--JuneTwoThousandTwentyFiveMember_zmsvL3G56K8f" title="Number of shares issued">15,000,000</span> at $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20220707__us-gaap--AwardDateAxis__custom--JuneTwoThousandTwentyFiveMember_zMXK1ieaibT1" title="Share price">0.08</span> expiring June 2025 and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220705__20220707__us-gaap--AwardDateAxis__custom--DecemberTwoThousandTwentyTwoMember_zaJsNjNhkGPg">5,000,000</span> at $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20220707__us-gaap--AwardDateAxis__custom--DecemberTwoThousandTwentyTwoMember_z7m2cDnGbbBb" title="Share price">0.01</span> expiring December 2022) for $<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220707__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA7FQfcBnMVb" title="Warrants and rights outstanding">20,000</span>.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted Stock Units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zhj8jNbsUEUb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s restricted stock units:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B0_zHoVDhwp7i01" style="display: none">SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/>Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Grant Date</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Balance at December 31, 2020 and 2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zifE6VQJGVyl" style="width: 14%; text-align: right" title="Number of Shares, RSU's Beginning balance">262,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20201231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zzlxDh8MsEw8" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Beginning balance">0.59</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSU’s granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zxaHUeQAVll1" style="text-align: right" title="Number of Shares, RSU's granted">42,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zp1MY2ghCkq9" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSU’s vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z16gYkTegPT" style="text-align: right" title="Number of Shares, RSU's vested">(17,700,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zClu1tw6yPO8" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="-sec-ix-hidden: xdx2ixbrl1409">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">RSU’s forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zGpwNcYrz2H1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSU's forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1411">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_znFCzpwFWWk5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1413">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zXjE4sVZmtbh" style="text-align: right" title="Number of Shares, RSU's Beginning balance">25,262,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z2tqexX3Vzsd" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_pdd" style="text-align: right" title="Number of Shares, RSU's granted">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zYWM2ni8usW9" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted">0.082</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">RSUs vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zepV7ipXnqE4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSU's vested">(10,100,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="-sec-ix-hidden: xdx2ixbrl1425">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSU's Ending balance">15,262,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Ending balance">0.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zA7p2pQstNq3" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022 and 2021, the Company recognized $<span id="xdx_905_eus-gaap--RestrictedStockExpense_c20220101__20220930_zXJq8gWvl2f3" title="Restricted stock expense vesting">908,200</span> and $<span id="xdx_90C_eus-gaap--RestrictedStockExpense_c20210101__20210930_zfJ5dlN8VTvf" title="Restricted stock expense vesting">1,614,000</span> worth of expense related to the vesting of its RSU’s. As of September 30, 2022, the Company had $<span id="xdx_908_ecustom--RestrictedStockExpensesYetToBeRecognized_c20220101__20220930_zYKPKI5MPAlg" title="Restricted stock expenses yet to be recognized">1,505,400</span> worth of expense yet to be recognized for RSU’s not yet vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 3, 2021, the Company has granted <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTUohliGPoL4" title="Number of restricted shares unit granted">12,000,000</span> RSUs to a consultant that vest on the grant date, and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zY99aQ2TX7D3" title="Number of restricted shares unit granted">700,000</span> RSUs to consultants that vest on the grant date. The Company has issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210601__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--OneConsultantsMember_zYpAa1LPPTha" title="Number of shares issued">12,000,000</span> common shares to the one consultant in June 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 3, 2021, as part of an Employment Agreement with the CEO, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zmHxwIwNBGHi" title="Number of restricted shares granted">30,000,000</span> RSUs to the CEO. Of the <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zKBXhLchow61" title="Number of restricted shares unit granted">30,000,000</span> RSUs, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_z06ouQ6vuqgd" title="Number of restricted shares unit vested">15,000,000</span> of them vest as follows: <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--StatementScenarioAxis__custom--OnTheGrantDateMember_zwbICUuyahk5" title="Number of shares vested on grant date">5,000,000</span> on the grant date, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zy7y558f9Lfl" title="Number of shares grant date">5,000,000</span> on the first anniversary and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zJ5HbK7HK8Zh" title="Number of RSU shares grant">5,000,000</span> on the second anniversary. The remaining <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zaOyU3WEmum" title="RSUs vested as performance based grants">15,000,000</span> RSUs vest as performance-based grants, with the Board of Directors determining the criteria of each <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210502__20210503__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zj2N366B9Q05" title="Number of shares grant date">5,000,000</span> RUSs at the nine-month anniversary, eighteen-month anniversary and twenty-seven month anniversary intervals. The Board of Directors has 90 days from May 3, 2021 to determine the performance criteria.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 3, 2022, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20220202__20220203__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zKD5xzqRmaM4" title="Restricted stock vested, shares">5,000,000</span> of the RSUs valued at $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220202__20220203__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zBKhPQUJXtpa" title="Restricted stock vested, value">450,000</span> to the CEO vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 3, 2022, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20220302__20220303__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z9A10iKgG4g8" title="Restricted stock vested, shares">5,000,000</span> of the RSUs valued at $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220302__20220303__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zwckDNcidl5k" title="Restricted stock vested, value">450,000</span> to the CEO vested.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2022, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220530__20220601__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zORo8g4rI6ni" title="Number of restricted shares unit granted">100,000</span> RSUs were granted to a consultant valued at $<span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue_c20220530__20220601__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1e9scMHkXSd" title="Number of restricted shares unit granted, value">8,200</span> that were vested immediately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</RDGL:CommonStockOptionsWarrantsAndRestrictedStockUnitsTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zV63mdIggoSg" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock options:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_z2QeqmsOmya4" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF CHANGES IN STOCK OPTION</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per Share</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per Share</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zkQ97FMTnJPb" style="width: 6%; text-align: right" title="Number of Options Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,885,461</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_z3Pz91Mxuu5h" title="Exercise Price Per Share Outstanding Beginning Balance">0.024</span>-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_ztK2oNqDawN4" title="Exercise Price Per Share Outstanding Beginning Balance">0.04</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zwzx4kIr0c2b" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning">5.57</span> years</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_zISJgGmv2t6e" style="width: 6%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,661,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20210101__20211231_zPQVrDpwyf8g" style="width: 6%; text-align: right" title="custom:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231_zzH0l6AzeeTg" style="text-align: right" title="Number of Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1172">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zWobyjZKETo3" style="text-align: right" title="Exercise Price Per Share granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20210101__20211231_zKETw9UVyPcj" style="text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20211231_zWYieVYOjGii" style="text-align: right" title="Number of Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zt301NbhGgP7" style="text-align: right" title="Exercise Price Per Share exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20210101__20211231_z0tR2nUv0CXe" style="text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options expired</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20210101__20211231_zJJPFWreJZ61" style="text-align: right" title="Number of Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24,132,652</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zMogXLrt6n6b" style="text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20210101__20211231_zvy7CmWLPXYa" style="text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at December 31, 2021</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930_zbBenj66uwaa" style="text-align: right" title="Number of Options Outstanding Beginning Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zUNpBGrc0nlj" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_z7yCLHDg9xm5" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.04</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z31TEPNICkci" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning">7.70</span> years</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20220930_zq7zYlBYiSqh" style="text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83,992</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iS_c20220101__20220930_zrZiomWQFHF6" style="text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20220930_zyLeToW3IKh5" style="text-align: right" title="Number of Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1202">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930_zr7pVPXC6in6" style="text-align: right" title="Exercise Price Per Share granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1204">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_ecustom--WeightedAverageExercisePricePerShareOptionsGranted_c20220101__20220930_z7NioRur9UL2" style="text-align: right" title="Weighted Average Exercise Price Per Share Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220930_zq1GGIGcmJGk" style="text-align: right" title="Number of Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1208">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930_zI8sFYG7nF3c" style="text-align: right" title="Exercise Price Per Share exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--WeightedAverageExercisePricePerShareOptionsExercised_c20220101__20220930_z5KrdBPI0SAe" style="text-align: right" title="Weighted Average Exercise Price Per Share Options exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1212">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options expired/canceled</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20220930_zyMA7rl0ayCl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1214">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930_z9A1xh7BqZgf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_ecustom--WeightedAverageExercisePricePerShareOptionsExpired_c20220101__20220930_zJbFXmIFgXG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Options expired/cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220930_z9OAVsUVS9da" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding Ending Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zMyps7093AE5" title="Weighted Average Exercise Price Per Share Outstanding Ending">0.024</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_z2TuKMPD6lo5">0.04</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930_zfA2vBXjnLsg" title="Weighted Average Remaining Contractual Life (in years) Outstanding, Ending">6.95</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20220101__20220930_zw1fGaPDEDre" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,901</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice_iE_c20220101__20220930_ztfGzd93JXBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20220930_z5qFekDsuHY7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,252,809</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zY94ykyEmQah" title="Exercise Price Per Share Exercisable">0.024</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zEDHegetWTS3" title="Exercise Price Per Share Exercisable">0.04</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930_zG3LmWaMuFrk" title="Weighted Average Remaining Contractual Life (in years) Exercisable">6.95</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20220101__20220930_zi6l6YpnKhf5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,901</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares_iE_c20220101__20220930_zj8m3o5sL6Bg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 28885461 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.024 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 0.04 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31"> P5Y6M25D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 1661429 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<RDGL:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice contextRef="AsOf2020-12-31" decimals="INF" unitRef="USDPShares"> 0.05 </RDGL:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2021-01-012021-12-31" decimals="INF" unitRef="Shares"> 2500000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2021-01-012021-12-31" decimals="INF" unitRef="Shares"> 24132652 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 2252809 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.024 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 0.04 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31"> P7Y8M12D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 83992 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<RDGL:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.04 </RDGL:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 2252809 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-09-30_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.024 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-09-30_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 0.04 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-09-30"> P6Y11M12D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 30901 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<RDGL:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice contextRef="AsOf2022-09-30" decimals="INF" unitRef="USDPShares"> 0.04 </RDGL:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 2252809 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2022-09-30_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.024 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2022-09-30_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 0.04 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-01to2022-09-30"> P6Y11M12D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 30901 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares contextRef="AsOf2022-09-30" decimals="INF" unitRef="USDPShares"> 0.04 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 2500000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<RDGL:StockIssuedDuringPeriodSharesStockOptionsRescinded contextRef="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 24120152 </RDGL:StockIssuedDuringPeriodSharesStockOptionsRescinded>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 12500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensation contextRef="From2022-01-012022-09-30_us-gaap_StockOptionMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2021-01-012021-09-30_us-gaap_StockOptionMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensation>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zvw6s9PB9bHc" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s stock warrants:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zzoLSVxaIgf3" style="display: none">SCHEDULE OF CHANGES IN STOCK WARRANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted<br/> Average </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted<br/> Average</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Number Of<br/></p> <p style="margin-top: 0; margin-bottom: 0">Shares</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Exercise</p> <p style="margin-top: 0; margin-bottom: 0">Price Per</p> <p style="margin-top: 0; margin-bottom: 0">Share</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; font-size: 8pt; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining Contractual</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life</span></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 8pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Aggregate<br/></p> <p style="margin-top: 0; margin-bottom: 0">Intrinsic</p> <p style="margin-top: 0; margin-bottom: 0">Value</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Exercise<br/></p> <p style="margin-top: 0; margin-bottom: 0">Price Per</p> <p style="margin-top: 0; margin-bottom: 0">Share</p></td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%">Balance at December 31, 2020</td><td style="width: 1%"> </td> <td style="width: 2%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zNcdvUCWnBs1" style="width: 8%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">32,064,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z5njX0lhyaaa" title="Exercise Price Per Share Warrants Outstanding Beginning">0.04</span>-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise Price Per Share Warrants Outstanding Ending">80.00</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5jybTMi3At9" title="Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning">1.65</span> years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZV0lYigc5rd" style="width: 8%; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">1,614,567</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ExercisePriceMinimum_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpgEyizuaKP5" style="width: 8%; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning">0.06</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztWikh6uFKMg" style="text-align: right" title="Number of Shares, Warrants granted">11,237,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4HFiJapn6C9" title="Exercise Price Per Share Warrants granted">0.10</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeEwFWipfghf" style="text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVj5Lofdf7A7" style="text-align: right" title="Number of Shares, Warrants exercised">(10,730,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBkwl09KF4cd" style="text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants expired/cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZRFEcfqQfqi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants expired/cancelled">(709,375</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkaB4oYePS3e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1279">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwEqzjVZLT3g" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">31,862,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zaAlvwc7rTN9" title="Exercise Price Per Share Warrants Outstanding Beginning">0.04</span>-<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zG1ZkFwToyll" title="Exercise Price Per Share Warrants Outstanding Beginning">0.10</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziiKQ9zrkPMa" title="Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning">1.02</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVFoIBZVrazk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Beginning">538,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ExercisePriceMinimum_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z44yHMlfeAPh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zW9S6HacOyx9" style="text-align: right" title="Number of Shares, Warrants granted">20,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJo8o5JgIt7g" style="text-align: right" title="Exercise Price Per Share Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1295">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ExcercisePriceWarrantsGrantedMinimum_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zavBrZDRNz34" style="text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1297">-</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOIDkymvqVB9" style="text-align: right" title="Number of Shares, Warrants exercised">(825,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVHFgMKctHyj" style="text-align: right" title="Exercise Price Per Share Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants expired/cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4xG20NHO0l3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants expired/cancelled">(1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrrwB4XgXowg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercise Price Per Share Warrants expired/cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWlwbTvqEeQ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">50,037,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zI6yjoDGglO8" title="Exercise Price Per Share Warrants Outstanding Ending">0.04</span>-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_ztLZJYhFDfb2" title="Exercise Price Per Share Warrants Outstanding Ending">0.10</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zun3KHhqbko5" title="Weighted Average Remaining Contractual Life Warrants Outstanding Ending">1.04</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1eBPpnwDf7a" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding Ending">205,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ExercisePriceMinimum_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqhG43lGm6qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Ending">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z48ycAmwbaFd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable Ending">50,037,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zxIl1eK89Yb1" title="Exercise Price Per Share Exercisable">0.04</span>-<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSBhmpZHz8Pf" title="Exercise Price Per Share Exercisable">0.10</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq576MYfwbL5" title="Weighted Average Remaining Contractual Life Warrants Exercisable">1.04</span> years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zh35XsHIZh52" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Exercisable">205,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQYMMsgRCuJe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable">0.07</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> </tr> </table>
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 32064375 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.04 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 80.00 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"> P1Y7M24D </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2020-12-31_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 1614567 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
<RDGL:ExercisePriceMinimum contextRef="AsOf2020-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="USDPShares"> 0.06 </RDGL:ExercisePriceMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 11237500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="USDPShares"> 0.10 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 10730000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 709375 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 31862500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.04 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 0.10 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember"> P1Y7D </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 538875 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
<RDGL:ExercisePriceMinimum contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="USDPShares"> 0.07 </RDGL:ExercisePriceMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 825000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 1000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2022-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 50037500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-09-30_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.04 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-09-30_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 0.10 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember"> P1Y14D </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2022-09-30_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 205000 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
<RDGL:ExercisePriceMinimum contextRef="AsOf2022-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="USDPShares"> 0.07 </RDGL:ExercisePriceMinimum>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2022-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 50037500 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice contextRef="AsOf2022-09-30_us-gaap_WarrantMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.04 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice contextRef="AsOf2022-09-30_us-gaap_WarrantMember_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 0.10 </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice>
<RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember"> P1Y14D </RDGL:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageRemainingContractualTerm1>
<RDGL:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1 contextRef="AsOf2022-09-30_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 205000 </RDGL:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1>
<RDGL:WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable contextRef="AsOf2022-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="USDPShares"> 0.07 </RDGL:WeightedAverageExercisePricePerShareExercisePriceWarrantExercisable>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zAzMG62l64N" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each option/warrant is estimated using the Black-Scholes valuation model. The following assumptions were used for the periods as follows:</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zvyB1NeI56o9" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN FAIR VALUE MEASUREMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-size: 8pt"> </td> <td colspan="2" style="font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p></td><td style="font-size: 8pt"> </td><td style="font-size: 8pt"> </td> <td colspan="2" style="font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ended</b></span></p></td><td style="font-size: 8pt"> </td> </tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-size: 8pt; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 8pt"> </td><td style="font-size: 8pt; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt; font-size: 8pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zzZCuVzF1GI">.5</span> – <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zqqxhkRcX6Hg">3</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zsYh3ExgYWag" title="Expected term">2</span> - <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zDKLJcNw0mHg" title="Expected term">5</span> years</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20220930_zuIpGYEV9zP4" style="width: 14%; text-align: right" title="Expected volatility">66</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zL0XrJBtzrqi" title="Expected volatility">109</span> - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zG7FuuCoN5qd" title="Expected volatility">147</span></span></td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220930_z59FVUTJaaJh" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231_zhglHlLGtX69" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20220930_zT65hLhMc1q1" style="text-align: right" title="Risk-free interest rate">3</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zUx8Waljk9Wf" title="Risk-free interest rate">0.20</span> - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zkFkCICtqZAg" title="Risk-free interest rate">0.58</span></span></td><td style="text-align: left">%</td> </tr> </table>
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-09-30_srt_MinimumMember"> P0Y6M </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-09-30_srt_MaximumMember"> P3Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_srt_MinimumMember"> P2Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_srt_MaximumMember"> P5Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2022-01-01to2022-09-30" decimals="INF" unitRef="Pure"> 0.66 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2021-01-012021-12-31_srt_MinimumMember" decimals="INF" unitRef="Pure"> 1.09 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2021-01-012021-12-31_srt_MaximumMember" decimals="INF" unitRef="Pure"> 1.47 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2022-01-01to2022-09-30" decimals="INF" unitRef="Pure"> 0.03 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2021-01-012021-12-31_srt_MinimumMember" decimals="INF" unitRef="Pure"> 0.0020 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2021-01-012021-12-31_srt_MaximumMember" decimals="INF" unitRef="Pure"> 0.0058 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-082021-01-29_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3870428 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2021-01-082021-01-29_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 5430000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-03-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 11237500 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2021-03-012021-03-31_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 11238 </us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-03-31_us-gaap_WarrantMember" decimals="INF" unitRef="USDPShares"> 0.10 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-07-092021-09-24_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 838195 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2021-07-092021-09-24_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 1800000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-10-012021-10-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 2005693 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2021-10-012021-10-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 3500000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-03-012022-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 299577 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2022-03-012022-03-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 825000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
<RDGL:WarrantsExpired contextRef="From2022-05-292022-06-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 1000000 </RDGL:WarrantsExpired>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-07-052022-07-07_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 15000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharePrice contextRef="AsOf2022-07-07_us-gaap_CommonStockMember" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:SharePrice>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2022-07-052022-07-07_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 1200000 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2022-07-07_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-07-052022-07-07_custom_JuneTwoThousandTwentyFiveMember" decimals="INF" unitRef="Shares"> 15000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharePrice contextRef="AsOf2022-07-07_custom_JuneTwoThousandTwentyFiveMember" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:SharePrice>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2022-07-052022-07-07_custom_DecemberTwoThousandTwentyTwoMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharePrice contextRef="AsOf2022-07-07_custom_DecemberTwoThousandTwentyTwoMember" decimals="INF" unitRef="USDPShares"> 0.01 </us-gaap:SharePrice>
<us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2022-07-07_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 20000 </us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zhj8jNbsUEUb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule summarizes the changes in the Company’s restricted stock units:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B0_zHoVDhwp7i01" style="display: none">SCHEDULE OF CHANGES IN RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted <br/>Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Grant Date</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Balance at December 31, 2020 and 2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zifE6VQJGVyl" style="width: 14%; text-align: right" title="Number of Shares, RSU's Beginning balance">262,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20201231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zzlxDh8MsEw8" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Beginning balance">0.59</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">RSU’s granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zxaHUeQAVll1" style="text-align: right" title="Number of Shares, RSU's granted">42,700,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zp1MY2ghCkq9" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSU’s vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z16gYkTegPT" style="text-align: right" title="Number of Shares, RSU's vested">(17,700,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zClu1tw6yPO8" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="-sec-ix-hidden: xdx2ixbrl1409">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">RSU’s forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zGpwNcYrz2H1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSU's forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1411">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_znFCzpwFWWk5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1413">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance at December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zXjE4sVZmtbh" style="text-align: right" title="Number of Shares, RSU's Beginning balance">25,262,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20211231__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z2tqexX3Vzsd" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning">0.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_pdd" style="text-align: right" title="Number of Shares, RSU's granted">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zYWM2ni8usW9" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSU's granted">0.082</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">RSUs vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_zepV7ipXnqE4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, RSU's vested">(10,100,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's vested"><span style="-sec-ix-hidden: xdx2ixbrl1425">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance at September 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, RSU's Ending balance">15,262,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20220930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, RSU's Ending balance">0.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2020-12-31_custom_RestrictedStockUnitsMember" decimals="INF" unitRef="Shares"> 262500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31_custom_RestrictedStockUnitsMember" decimals="INF" unitRef="USDPShares"> 0.59 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-01-012021-12-31_custom_RestrictedStockUnitsMember30990828" decimals="INF" unitRef="Shares"> 42700000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2021-01-012021-12-31_custom_RestrictedStockUnitsMember30990828" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2021-01-012021-12-31_custom_RestrictedStockUnitsMember30990828" decimals="INF" unitRef="Shares"> 17700000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2021-12-31_custom_RestrictedStockUnitsMember" decimals="INF" unitRef="Shares"> 25262500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2021-12-31_custom_RestrictedStockUnitsMember" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2022-01-012022-09-30_custom_RestrictedStockUnitsMember30990859" decimals="INF" unitRef="Shares"> 100000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2022-01-012022-09-30_custom_RestrictedStockUnitsMember30990859" decimals="INF" unitRef="USDPShares"> 0.082 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2022-01-012022-09-30_custom_RestrictedStockUnitsMember30990859" decimals="INF" unitRef="Shares"> 10100000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2022-09-30_custom_RestrictedStockUnitsMember" decimals="INF" unitRef="Shares"> 15262500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2022-09-30_custom_RestrictedStockUnitsMember" decimals="INF" unitRef="USDPShares"> 0.08 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:RestrictedStockExpense contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 908200 </us-gaap:RestrictedStockExpense>
<us-gaap:RestrictedStockExpense contextRef="From2021-01-012021-09-30" decimals="0" unitRef="USD"> 1614000 </us-gaap:RestrictedStockExpense>
<RDGL:RestrictedStockExpensesYetToBeRecognized contextRef="From2022-01-01to2022-09-30" decimals="0" unitRef="USD"> 1505400 </RDGL:RestrictedStockExpensesYetToBeRecognized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" unitRef="Shares"> 12000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_ConsultantsMember" decimals="INF" unitRef="Shares"> 700000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-06-012021-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_OneConsultantsMember" decimals="INF" unitRef="Shares"> 12000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 30000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember" decimals="INF" unitRef="Shares"> 30000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember" decimals="INF" unitRef="Shares"> 15000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_custom_OnTheGrantDateMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember" decimals="INF" unitRef="Shares"> 15000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-05-022021-05-03_us-gaap_RestrictedStockUnitsRSUMember_custom_EmploymentAgreementMember_custom_BoardOfDirectorsMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2022-02-022022-02-03_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-02-022022-02-03_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember" decimals="0" unitRef="USD"> 450000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2022-03-022022-03-03_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2022-03-022022-03-03_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember" decimals="0" unitRef="USD"> 450000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2022-05-302022-06-01_custom_ConsultantMember_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" unitRef="Shares"> 100000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<RDGL:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue contextRef="From2022-05-302022-06-01_custom_ConsultantMember_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" unitRef="USD"> 8200 </RDGL:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue>
<us-gaap:CommitmentsDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">
<p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_zuUTvhxoITWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6: <span id="xdx_829_zAUqb2B4vs13">COMMITMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. <span id="xdx_90B_ecustom--AgreementTermDescription_c20190603__20190604__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_zxNuNBn7Pzs5" title="Agreement term description">The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $<span id="xdx_90E_eus-gaap--OfficersCompensation_c20190603__20190604__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_zHRbQbi2qn1k" title="Compensation amount">225,000</span>. In addition, there is a discretionary bonus to be earned in the amount of $<span id="xdx_90E_ecustom--DiscretionaryBonus_c20190603__20190604__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--DrMichaelKKorenkoMember_zHAQZWzo1YRg" title="Discretionary bonus">7,500</span> per quarter upon the satisfaction of conditions to be determined by the Board of Directors of the Company.</span></p>
</us-gaap:CommitmentsDisclosureTextBlock>
<RDGL:AgreementTermDescription contextRef="From2019-06-032019-06-04_custom_EmploymentAgreementMember_custom_DrMichaelKKorenkoMember"> The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. The Company on December 31, 2020 extended this agreement through December 31, 2021 while renegotiating terms of a new Employment Agreement. On May 3, 2021, the Company and the Chief Executive Officer agreed the terms of a new Employment Agreement with an effective date of January 1, 2021 that has a term of three years and expires December 31, 2023 </RDGL:AgreementTermDescription>
<us-gaap:OfficersCompensation contextRef="From2019-06-032019-06-04_custom_EmploymentAgreementMember_custom_DrMichaelKKorenkoMember" decimals="0" unitRef="USD"> 225000 </us-gaap:OfficersCompensation>
<RDGL:DiscretionaryBonus contextRef="From2019-06-032019-06-04_custom_EmploymentAgreementMember_custom_DrMichaelKKorenkoMember" decimals="0" unitRef="USD"> 7500 </RDGL:DiscretionaryBonus>
</xbrl>

↑Top
Filing Submission 0001493152-22-028874   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sun., May 5, 4:46:07.2pm ET